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Multiple sclerosis (MS) is the most frequent demyelinating disease of the central 
nervous system (CNS), affecting about 2 million individuals worldwide. The disease 
remains a major public health issue as the leading cause of non-traumatic neurological 
disability among young adults. Significant progress has been made in the past decades 
to address the inflammatory component of the disease, which has lead to the emergence 
of more successful disease modifying therapies (DMT) and to better clinical outcomes 
for patients at least in the early phases of the disease. Yet our picture of MS remains 
fuzzy at best, and our reach in terms of therapy limited as none of the drugs currently 
available has been shown to successfully prevent disability progression.  
 
The classical dichotomy between inflammation and neurodegeneration had to be 
challenged to further our understanding of progression in MS. While inflammatory and 
demyelinating lesions of the white matter (WM) remain the hallmark of the disease and 
the most characteristic marker for diagnosis, grey matter (GM) changes and in 
particular neuronal damage is now thought to play a major role in the neurological 
decline of MS patients. Recognizing that besides myelin, synapses, dendrites and 
neurons are early targets of the disease process could have profound therapeutic 
implications. While this has been suggested in post-mortem tissue samples, further 
evidence in patients at different stages of the disease is critically needed. Several have 
tried to measure neurodegeneration in vivo using brain volumetry or non-conventional 
magnetic resonance imaging (MRI). But these techniques for the most part lack 
specificity to the neuronal compartment. Thus the development of a new imaging 
technique able to specifically assess the neuronal component of GM damage in MS 
patients may have significant impact. 
 
[11C]Flumazenil (FMZ) is an antagonist of the central benzodiazepine (BZD) receptor, a 
component of the ubiquitous GABAA receptor complex present on neurons throughout 
the cortical and subcortical grey matter. [11C]FMZ positron emission tomography (PET) 
could possibly detect and quantify neuronal damage in the grey matter, and provide 
great insights into the pathophysiology of neurological decline in MS. This has been the 
working hypothesis of the work presented here. 
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This manuscript will first attempt to present current concepts of WM and GM damage 
in MS from a histological, immunological and neuroimaging point of view, highlighting 
the shift from inflammation to neurodegeneration in our understanding of disability 
progression. We’ll underscore the need for new imaging techniques specific of the 
neuronal compartment to fully capture the neurodegenerative process and its relevance 
over the course of the disease. In the second part of this work we will propose PET with 
[11C]-FMZ as potential marker of neuronal damage in MS by presenting the detailed 
methods and results of a pilot study conducted in relapsing remitting (RRMS) and 
secondary progressive MS (SPMS). Finally we will discuss our findings in the context of 
current and sometimes-conflicting ideas and theories of neurodegeneration in MS. We’ll 
aim to expand the scope of this work by presenting future avenues of research relevant 
to our topic.    
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1. GENERAL CONSIDERATIONS 
 
Since its first pictorial descriptions by Jean Cruveilhier in his Anatomie Pathologique du 
corps humain [1] and Robert Carswell in Pathological Anatomy: Illustrations of the 
Elementary Forms of Disease [2], followed by its identification and classification as a 
distinct entity by Jean Martin Charcot, we have come a long way in our ability to 
diagnose and document the features of la sclérose en plaques. Multiple Sclerosis is now 
recognized as one of the most common diseases of the central nervous system (CNS), 
and is a very active field of research.  
 
 
1.1. Epidemiology 
 
In a recent review of existing literature, Melcon et al. [3] estimated the median MS 
incidence at 5.2 (range 0.5-20.6) per 100.000 p-yrs and median prevalence at 
112/100.000 pop. Incidence and prevalence were found highest in North America. 
While low in childhood, MS incidence peaks between 20 and 40 years of age with a 
mean age of onset of symptoms often found around 30 years [4].  
What was thought as a predominantly male disease at the beginning of the 20th century 
is now known to affect women disproportionately. Sex ratios of about 2-2.5/1 have been 
frequently reported but could be as high as 4.1 in some US communities [5]. The sex 
prevalence of MS seems to undergo dynamic changes, with several recent examples of 
increasing sex ratios.  In Denmark, Koch-Henriksen and colleagues reported that the 
incidence of MS in men had remained virtually the same whereas that of women had 
doubled since 1970 [6]. This phenomenon may indicate potential environmental 
changes, not just a better diagnosis of benign cases in women.  
MS prevalence varies greatly between continents. As mentioned above, North America 
was found to have the highest incidence and prevalence in a recent study [3], followed 
by Europe. In contrast, South and East Asia, South America and North Africa had much 
lower rates. However the notion of a latitudinal gradient suggested by early 
epidemiologic studies is now being increasingly questioned as genetic and 
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environmental factors are thought to play a key role over geography in the prevalence 
and incidence of MS. Of particular interest, lower circulating levels of vitamin D have 
been associated with a higher risk of MS [7] [8]. It has also been shown that vitamin D 
levels are inversely associated with clinical relapses and MRI activity in MS patients [9]. 
Other environmental factors such as cigarette smoking [10] and Epstein-Barr virus 
infection [11] have been identified.  
 
 
1.2. Diagnosis of Multiple Sclerosis 
 
1.2.1. Clinical features 
 
Initial presentation can greatly vary from patient to patient. Common presenting 
symptoms include: optic neuritis, brainstem or spinal cord manifestations or in less 
frequent instances hemispheric symptomatology.  In up to one fourth of cases, 
symptoms at presentation may be multifocal [12]. When a patient presents with 
symptoms suggestive of WM tract damage, the exclusion of an alternate diagnosis is 
imperative before a diagnosis of MS can be made. Such diagnosis will then rely on the 
demonstration of “dissemination in space” (DIS), and “dissemination in time” (DIT) 
based on clinical grounds alone (clinically definite MS or CDMS) or a combination of 
clinical and radiological findings.  
A “relapse” is defined as “patient-reported symptoms or objectively observed signs 
typical of acute inflammatory demyelinating event in the CNS […] with duration of at 
least 24 hours, in the absence of fever or infection” [13]. Based on the McDonald criteria 
of the International Panel on Diagnosis of MS, initially published in 2001 [14], 
subsequently revised in 2005 [15] and 2010 [13], a diagnosis of MS can be reached on 
clinical findings alone if the patient presents with a history of 2 or more relapses and 
objective clinical evidence of 2 or more lesions. It should be expected for MRI findings 
to be consistent with a diagnosis of MS, though not mandatory in this case. In all other 
presentations (2 attacks with objective evidence of only one lesion, single relapse, 
progressive course), MRI will play a central role in demonstration of DIS and DIT. 
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1.2.2. Magnetic Resonance Imaging 
 
MRI is currently the most useful paraclinical tool for the diagnosis of MS. MS white 
matter plaques, the pathological hallmark of the disease, can be detected with great 
sensitivity particularly on T2-weighted or Fluid attenuated inversion recovery (FLAIR) 
sequences. Their objective presence on MRI is considered an essential requirement for 
the diagnosis of MS. These lesions are often periventricular with a characteristic ovoid 
shape, but can also be seen in juxtacortical or infratentorial areas (Figure 1).  
 
 
Figure 1: MS lesions visible as hyperintensities on FLAIR images. Left: Infratentorial lesion 
found in the pons (arrow). Middle: numerous periventricular lesions, some of which have 
classic ovoid shape (arrow). Right: subcortical lesions in frontal areas (arrows).  
 
 
MRI lesions enhancing after injection of Gadolinium (Figure 2) reflect active 
inflammation and breakdown of the blood-brain barrier (BBB) and are thus considered 
more recent (≤3 weeks on average). 
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Figure 2: MRI of the brain post-gadolinium injection in one MS patient. Periventricular 
lesions are seen as hyperintense foci on Flair image (left). Recent area of inflammation 
enhances after gadolinium injection on T1-weighted scan (right) 
 
Spinal cord lesions have been reported in up to 90% of MS patients [16] and 
asymptomatic lesions have been detected in up to one third of patients presenting with a 
demyelinating event suggestive of MS. Spinal cord MRI at time of diagnosis can thus be 
useful to demonstrate DIS of the disease process. Spinal cord lesions, however, much 
less frequently present with contrast enhancement and are therefore rarely useful for 
demonstration of DIT. It is currently not recommended to perform follow-up spinal 
MRI in CIS patients, as it seems to have limited value [17]. However, it is important to 
perform spinal MRI for differential diagnosis in patients presenting with symptoms 
suggestive of spinal cord demyelination [18]. Compressive myelopathy can easily be 
ruled out. Other disorders can present with spinal cord lesions and the topography and 
extent of the lesions should be critically analyzed. Particular consideration will need to 
be given to neuromyelitis optica (NMO). In MS, short-segment lesions (figure 3) are the 
rule, whereas NMO lesions are longitudinally expansive (more than three vertebral 
segments in length) on sagittal views. MS lesions are often located on the periphery of 
the cord on axial views. They contrast with NMO lesions, which are often central and 
expand axially within the spinal GM. 
 20 
                    
Figure 3: Active cervical cord lesion in MS on sagittal MRI. Lesion is visible as T2 
hyperintensity (left) and enhances after Gadolinium injection on T1-weighted scan (right). 
MS lesions typically extend over <2 vertebral segments.  
 
While earlier diagnostic criteria using MRI were based on lesion number [19], revised 
and simplified criteria by Swanton and colleagues now focus on lesion location 
(periventricular, juxtacortical, infratentorial, spinal cord) for demonstration of DIS [20]. 
Confirmation of DIT can be achieved on a single MRI with presence of enhancing and 
non-enhancing lesions, or otherwise by detection of additional lesions on follow-up 
scans. The revised McDonald criteria have the clear objective of allowing early diagnosis 
of MS in patients presenting with typical symptoms of CNS demyelination. Still, the risk 
of over-diagnosing MS remains real and as the Magnetic Resonance Imaging in MS 
(MAGNIMS) committee recently recommended: “MRI scans should be interpreted by 
experienced readers who are aware of the patient’s clinical and laboratory information” 
[17]. 
 21 
1.2.3. Summary of 2010 revision of McDonald criteria   
         
Table 1: 2010 revised McDonald criteria for diagnosis of MS (from Polman et al., Annals of 
Neurology, 2011) [13] 
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1.3. Evolution and prognosis 
 
1.3.1. Clinical phenotypes 
 
Clarity and consistency in defining clinical phenotypes is essential for demographic 
studies, clinical trials and management of therapy in clinical practice. Newly revised 
classification proposed by Lublin and colleagues [21] recommends that patient 
phenotype be assessed on clinical grounds with input from imaging studies when 
needed. According to the new consensus, 3 disease phenotypes can be defined: clinically 
isolated syndrome, relapsing-remitting disease, and progressive disease including 
primary progressive and secondary progressive. 
Clinically Isolated Syndromes (CIS) refer to the initial clinical presentation of the 
disease in patients with symptoms typical of demyelination of the CNS WM tracts, but 
who fail to show evidence of dissemination in time of the disease process. Patients with 
CIS may “convert” to definite MS if they meet criteria for DIS and DIT on clinical or 
radiological grounds.   
A majority of patients diagnosed with definite MS will follow a relapsing remitting (RR) 
disease course characterized by exacerbations (relapses) with periods of clinical stability 
in between. Patients may recover fully or partially from relapses (figure 3-top). On the 
opposite end of the spectrum, 15% experience a gradual worsening from onset with no 
initial exacerbations (primary progressive course, figure 3- bottom)  
Patients with an initial RR form of the disease may subsequently experience progression 
independently of relapse activity. This phenomenon is called secondary progression (SP, 
figure 3-middle). It is important to note that progressive disease (SPMS or PPMS) does 
not progress in a uniform fashion and patients may experience periods of relative 
clinical stability.  
Assessment of disease activity may provide insights into individual prognosis and guide 
patient management. Thus, current consensus recommendations have included disease 
activity as a modifier of basic phenotype courses mentioned above. Clinical activity is 
defined by relapses or radiological activity (presence of contrast-enhancing lesions, new 
or unequivocally enlarged T2 lesions).  
 23 
 
 Figure 4: Clinical phenotypes of MS: Relapsing Remitting MS (RRMS, top) without (left) 
and with (right) accumulation of neurological deficits, Secondary progressive MS (SPMS, 
middle) without (left) or with (right) clinical exacerbations and primary progressive MS 
(PPMS, bottom) with linear course (left) or periods of relative stability (right). 
 
With widespread availability of MRI, we have seen an increase in incidental abnormal 
findings. Radiologically isolated syndromes (RIS) are defined as MRI findings 
suggestive of MS in persons without typical MS symptoms and with normal neurological 
findings. This entity was recently introduced in the phenotypic description by Lublin et 
al. [21]. RIS individuals often have brain MRI performed for reasons such as headaches 
[22]. Okuda et al. [23] proposed a formal definition of RIS. The RIS Consortium 
recently presented the results of a retrospective study of 451 RIS subjects from 22 
databases in 5 countries [24].   This study showed that 34% of RIS individuals would 
develop an initial clinical event within 5 years of RIS diagnosis. Age < 37 years, male sex, 
and spinal cord involvement appear to be the most important independent predictors of 
symptom onset. Prospective follow-up of RIS subjects should shed more light on this 
entity and help define the basis for treatment with disease modifying therapies (DMTs). 
 
 
 
 24 
1.3.2. Prognosis and prediction 
 
It is important to understand clinical phenotypes as a dynamic process. Patient with CIS 
may convert to RRMS, and patients with RRMS may subsequently follow a SP course. 
Brownlee et al. [25] followed 157 patients with CIS over 6 years: 71 (45%) had a second 
attack and thus developed clinically definite MS, 36 (23%) had MRI-only MS, and 50 
(32%) didn’t have MS according to 2010 McDonald criteria at the end of the follow-up 
period. Several independent risks factors for conversion to MS have been identified:  
young age [26], presence of cognitive impairment at onset [27], genetic factors such as 
HLA-DRB1 [28], and vitamin D deficiency [8]. One of the most significant predictors of 
conversion to MS from CIS is the presence of brain abnormalities on baseline MRI [29], 
with number, location and activity of the lesions all providing prognostic information.  
While relapses may have unforgiving consequences in rare cases, the socio-economic 
impact of the disease is driven by the increasing and unrelenting disability progression 
that can follow the RR phase. Scalfari et al. recently provided a review of the London 
Ontario MS database [30], which evaluated 806 patients annually or semi-annually for 
28 years (shortest follow-up=16 years). None of the patients received DMTs. At the end 
of the study period, 66.3% of patients had developed a SP course. The authors 
demonstrated that the rate of conversion to SPMS increases proportionally to disease 
duration. However they highlighted the fact that individual prognosis was highly 
variable. About 25% of patients will become progressive within 5 years of onset of the 
disease, while on the opposite end of the spectrum, 25% of patients will remain RR at 15 
years. This natural history study confirmed previous findings suggesting that male sex 
[31] and older age of onset [32] were significant risk factors for conversion to SPMS. The 
role of early clinical activity in the probability and latency of secondary progression 
remains debated. Annual relapse rates are today the primary endpoint of many 
controlled clinical trials, and some have argued it could be used as a surrogate for 
disability progression [33].  Total relapse numbers were however found to have no or 
little significant effect on the risk of progression, the latency to onset of the SP phase or 
attainment of high disability levels [34] [35].  
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Beyond conversion to SP course, physical disability in the clinical setting or in research 
trials can be assessed using the Expanded Disease Severity Scale (EDSS, Annex A). This 
scale quantifies disability in eight functional systems (FS). These ratings are then used 
in conjunction with observations and information concerning gait and use of assistive 
devices to rate the EDSS from 0 (normal neurological examination) to 10 (death due to 
MS). In a recent publication [36], Tintore et al. performed multivariate analyses 
incorporating not only demographic and clinical data but also MRI and biological 
variables to determine the risk of attaining EDSS= 3.0 in individual patients. Their 
comprehensive work on a prospective cohort of 1015 patients with CIS highlights the 
importance of radiological and biological metrics to more accurately assess early risk of 
disability. They found that oligoclonal bands in the cerebro-spinal fluid (CSF), as well as 
the presence of over 10 lesions on baseline MRI were associated with a higher risk of 
accumulation of disability (up to EDSS= 3.0) with adjusted hazard ratios of 2.0 (95% CI 
1.2–3.6) and 2.9 (95% CI 1.4– 6.0). In a presentation at the latest ECTRIMS meeting 
(Barcelona, 7-10 October 2015), the authors presented a more dynamic prediction 
model, which included not only baseline metrics but also data acquired at one year after 
CIS diagnosis. Again, MRI metrics such as new T2 lesions at 1 year were identified as 
relevant prognostic markers that modified baseline risk score at 12 months. The 
inclusion of dynamic variables improved risk prediction, with a reasonable C-statistic of 
0.75. The model however was not designed to predict the risk of disability beyond 
EDSS=3.0 or the risk of entering a secondary progressive course.  
Beyond the early stages of the disease, focal MS pathology appears less relevant to 
disease progression. Particularly, once a threshold of disability is reached, progression 
may not be influenced by relapses either before or after onset of the SP phase [37]. Leray 
and colleagues [38] proposed the concept of MS as a 2-stage disease. The early phase is 
defined from clinical onset to irreversible EDSS= 3.0 and is thought to be mainly 
dependent on focal damage to the WM. The second or late phase, from irreversible 
EDSS=3.0 to irreversible EDSS=6.0, is thought to be independent of focal inflammation 
and may instead be underpinned by diffuse inflammatory and neurodegenerative 
changes. In an observational study of 2054 patients referred to the Rennes MS clinic, 
the authors were able to show that disability progression in the first phase of MS does 
not influence progression during the second phase. Duration of the early phase was 
 26 
found to be highly variable while the duration of the late phase was remarkably 
constant, as illustrated in figure 5. The dissociation between the 2 phases of MS, with 
different underlying mechanisms, is supported by MRI evidence. Calabrese et al. 
followed RRMS patients with at least 5 years of clinical history (mean>10 years) and 
showed that at this stage, variables such as T2 lesion volume did not influence the risk of 
entering the secondary progressive phase of the disease [39].    
 
 
Figure 5: Duration of the 2 phases of MS (from Leray et al., Brain, 2010). Disability 
progression during Phase 2 (mean time from EDSS 3 to EDSS 6) in five subgroups defined 
according to the duration of Phase 1 (mean time from MS clinical onset to EDSS 3) in 718 
MS patients who have reached both EDSS 3 and EDSS 6. 
 
Patient prognostication is a complex and dynamic task in MS, as different clinical, 
radiological and biological factors can influence outcome depending on the disease 
stage. This reality reflects the variety of pathological mechanisms thought to underpin 
disability progression in MS, which will be discussed in a later section 
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1.3.3. Disease-modifying therapies available in 2015 
 
The last 20 years have seen the emergence and systematic use of DMT in MS.  There are 
currently 13 FDA-approved therapies with many more emerging drugs under trial or 
consideration. Available DMTs primarily target the inflammatory process of the disease 
and their mechanisms of action are illustrated in figure 4.  
This major development in the MS therapeutic arsenal has almost exclusively benefitted 
patients with RRMS. All currently approved therapies have been shown to prevent, with 
varying degrees of efficacy, exacerbations and new brain T2 and Gadolinium enhancing 
lesions in RRMS. When studied in CIS, first line injectable immunomodulators such as 
glatiramer acetate (GA) or interferons (IFN) also reduced the risk of conversion into 
clinically definite MS [40]. 
The notion of “sustained disability progression”, as used in RRMS clinical trial 
outcomes is defined as a worsening of EDSS performance that persists for 3 to 6 
months. As noted by Lublin et al. [21], worsening in RRMS can occur in the context of 
multiple attacks, poor recovery after severe exacerbation or true onset of a progressive 
phase. Kalincik et al., recently suggested that disability outcomes of clinical trials based 
on 3-6 months “confirmed disability progression” overestimate the accumulation of 
permanent disability by 30% [41]. Consequently reported effects on “sustained disability 
progression” may not reflect actual efficacy on the accrual of disability occuring 
independently of relapse activity. In fact, when tested in SP or PPMS, none of the 
currently available therapies have demonstrated any effect in slowing progression or 
reversing disability, leaving about half of the MS patient population with a sense of 
neglect and frustration.  
It has become clear that the pathological processes driving the progressive phase of the 
disease differ from that of the RR phase. To develop future therapies able to slow, 
prevent or even reverse progression, we will need to understand the specificity of this 
disease process, especially the early phenomena contributing to the accumulation of 
disability. We will need to develop reliable biomarkers that can substitute for clinical 
endpoints to speed up drug development. Such biomarkers may also allow early 
identification of patients at risk of progression.  
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Figure 6: Illustration of mechanisms of action of currently available or in-trial MS 
therapies. APC = antigen presenting cell, BBB = blood–brain barrier, C5b-9 = complement 
complex 5b-9, CNS = central nervous system, FasL = Fas ligand, GA = glatiramer acetate, 
IFN = interferon, MHC I = major histocompatibility complex I, NO = nitrous oxide, Nrf2 = 
nuclear factor (erythrocyte derived) related factor 2, S-1-P1 = sphingosine-1-phosphate 1, 
TCR = T cell receptor, VCAM-1 = vascular cell adhesion molecule 1, VLA-4 = very late 
antigen 4. From Broadley et al., Journal of Clinical Neuroscience, 2014 [42]. 
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2.  MECHANISMS OF DISABILITY PROGRESSION 
 
2.1. White matter damage 
 
2.1.1. Focal demyelination and inflammation 
 
The pathological hallmark of the disease is the formation of WM plaques of 
demyelination. Clinical relapses are considered the physical expression of these WM 
lesions. In the early stages of the disease, active WM tissue demyelination within 
plaques is associated with significant inflammation, BBB damage and microglial 
activation. Inflammatory infiltrates composed of clonally activated CD8+ T-lymphocytes 
and to a lesser degree CD4+ T-lymphocytes and B-cells are characteristically detected 
around post-capillary venules or scattered throughout the brain parechyma. Data 
suggest that the extent of T- and B-cell infiltration correlates with the degree of 
demyelination in focal active lesions [43].  Remyelination can occur in MS lesions. This 
process is particularly stable and extensive in animal models of the disease, but more 
limited in a majority of MS patients. A study of 168 WM lesions showed that only 22% 
were completely remyelinated as “shadow plaques”, 73% partially remyelinated and 5% 
completely demyelinated [44].  
Axonal transection, also a prominent feature of acute and active lesions, appears related 
to local inflammatory changes [45] [46]. Several factors may contribute to axonal 
transection during acute inflammatory injury of the WM. Activated T-cells may initiate a 
pro-inflammatory cascade resulting in the production of interferon gamma, which will 
subsequently activate macrophages to produce nitric oxide (NO). NO is a potent 
mitochondrial inhibitor and will disrupt ATP synthesis. Excitotoxicity due to increased 
release of glutamate by microglial cells or macrophages during the inflammatory 
process may further hinder mitochondrial function. Glutamate release leads to 
overstimulation of glutamate receptors on the post-synaptic membrane of neurons and 
loss of calcium homeostasis. Increased intracellular calcium concentrations activate 
enzymes involved in cytoskeleton disruption, DNA damage and mitochondrial 
dysfunction, leading to acute loss of axonal integrity [47].  
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Focal damage to the WM can be particularly well appreciated using MRI. T2-weighted 
sequences can detect WM plaques with great sensitivity. Beyond the diagnostic process, 
MRI can help detect subclinical disease activity by the presence of contrast-enhancing 
lesions or presence of new/enlarging lesions on subsequent scans. These markers of 
disease activity are particularly useful to the clinician to evaluate response to therapies 
which currently target the inflammatory process of the disease.  Treatment non 
responders, or suboptimal responders, in whom a change of therapy should be 
considered, can thus be identified [17]. However, as we have seen earlier, MRI studies 
fail to show significant correlations between focal WM demyelination and inflammation 
and severity of progression, especially once the patient reaches a certain threshold of 
disability [48] [49] [39] [38].  
To this day, conventional MRI cannot differentiate WM lesions that are fully or partly 
remyelinated from fully demyelinated ones, though this may be of importance in our 
understanding of the impact of WM lesions. Indeed, experimental studies have 
established that remyelination may promote short-term neuronal function recovery and 
help prevent subsequent axonal degeneration, possibly via trophic effects of axon-
myelin interactions [50]. At the patient population level, studies of post-mortem tissue 
have shown diversity in the amount of remyelination between MS cases independently 
of the disease stage [51]. A patient may thus exhibit extensive or low remyelinating 
capacity. This was further confirmed by PET study of MS patients using radiotracer 
[11C]PIB, a thioflavine derivative sensitive to changes in myelin content in tissue (figure 
7) [52]. We recently longitudinal follow-up of MS patients with [11C]PIB PET to support 
the notion of a patient-specific “remyelination profile”. We demonstrated that patients’ 
dynamic remyelination potential was strongly associated with clinical scores (Bodini et 
al., manuscript in revision), bringing novel insights on the role of WM lesions in MS 
pathophysiology.   
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Figure 7: [11C]PIB  in MS. The uptake of [11C]PIB is lower in MS lesions compared with 
normal-appearing white matter in patients with MS, suggesting the presence of 
demyelination. (A) T1-weighted image and (B) corresponding map of [11C]PIB PET binding 
in a patient with MS, showing lower [11C]PIB uptake in the GM in general compared with 
WM and lower uptake in a MS lesion (arrow head) compared to normal-appearing WM. (C) 
Coregistration of images shown in (A) and (B). (D) Time–activity curve of the normal-
appearing WM (red) and the lesion seen in (A) (blue). PIB=thioflavine-T derivative 2-(40-
methylaminophenyl)-6-hydroxybenzothiazole. 
 
 
2.1.2. Diffuse white matter damage 
 
In the progressive phase of the disease, inflammation becomes much less pronounced 
within plaques. Overall the percentage of an individual’s lesions that are active declines 
as the disease evolves [53]. Lesions are either inactive or slowly expanding at the edges. 
Similarly, BBB leakage is much less evident [54]. This results in a decrease in frequency 
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of contrast-enhanced lesions and new/expanding T2 lesions on MRI, which become 
poor markers of evolution at this stage.  
A characteristic feature of progressive MS is diffuse pathology of brain tissue, outside of 
focal lesions. Abnormalities have been described in the so-called “normal-appearing 
WM” (NAWM), ie WM tissue that appears normal both on macroscopic examination 
and MRI [55]. Pathologically, almost 75% of macroscopically normal white matter 
samples have been found histologically abnormal [56]. Areas of “dirty-appearing WM” 
(DAWM) have also been characterized on MRI as having an intensity higher than that of 
the NAWM, but lower than focal lesions. DAWM can be found in direct proximity of 
focal lesions or in locations not related to WM lesions and may represent a separate 
pathologic entity [57]. 
Pathology of the normal appearing white matter (NAWM) has been well described by 
post-mortem studies and has been found to differ significantly from that of early focal 
WM plaques. Kutzelnigg et al. analyzed 52 post-mortem MS brains at different stages of 
the disease and provided a clear picture of the diffuse pathology affecting the WM [58] 
(figure 8). The authors reported a global reduction in myelin staining in the NAWM due 
to decreased fiber density as well as diffuse axonal injury, which is most significant in 
the progressive MS cases compared to RRMS or acute MS. Axonal pathology is evident 
by the presence of axonal swellings, axonal end-bulbs and degenerating axons 
throughout the WM. It may be of importance to note that axonal degeneration is 
increased around MS lesions and in tracts emerging from plaques. Inflammation is also 
diffuse at the later stages of the disease and consists of perivascular cuffs of 
mononuclear cells and diffuse tissue infiltration by T-lymphocytes. Scattered microglial 
activation is another significant component of NAWM pathology and is profound at the 
later stages of the disease. Activated microglia, while present diffusely in the NAWM, 
tend to aggregate in the periplaque of slowly expanding, also called smoldering, lesions 
where it is associated with ongoing axonal injury [53]. Microglial cells are the resident 
macrophages of the CNS and can be activated following tissue injury [59]. They can then 
adopt diverse phenotypes, either protective or driving the degenerative process of the 
disease. Studies in animal models of MS have suggested that blood-borne monocytes, 
morphologically indistinguishable from resident microglia, may also infiltrate the brain 
parenchyma and play an important role in potentiating axonal degeneration [60]. 
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Finally, meningeal inflammation, present at all stages of the disease, may influence the 
extent/topography of diffuse white matter damage. 
 
 
Figure 8: Pathology at different stages of the disease, acute MS (AMS), RRMS, PPMS and 
SPMS. White matter plaques (green) dominate the disease process in AMS and RRMS, 
while diffuse WM inflammatory infiltration (blue dots) and GM pathology (orange) are 
prevalent in PPMS and SPMS. From Kutzelnigg et al., Brain, 2005. 
 
Few post-mortem studies have specifically focused on the DAWM as a separate entity 
from the NAWM.  Moore et al. described a loss of myelin phospholipids that appeared 
intermediate between NAWM levels and that of focal plaques [61]. Seewann et al. 
reported in a larger number of subjects significant reduction of myelin density, 
extensive axonal loss and chronic gliosis [57]. Interestingly these changes appeared 
chronic in nature as no evidence of acute axonal damage, remyelination or BBB leakage 
were found.  
Several mechanisms may have a role in the extensive axonal damage reported outside of 
MS lesions. The findings observed in the DAWM support a secondary neuro-
degenerative process as a result of distant inflammatory lesional damage (wallerian 
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degeneration) [57]. Chronic demyelination in these areas may also imply loss of myelin 
trophic support, as suggested by evidence of axonal degeneration associated with 
genetic ablation of myelinating oligodendrocytes in animal models [50]. Loss of myelin 
staining in the NAWM however appears related to loss of fiber rather than primary 
demyelination. Recent studies in animal models have suggested that oligodendroglia 
may support axonal integrity through myelin-independent mechanisms. Impairment of 
these mechanisms may induce axonal damage without considerable demyelination. In 
particular, transport of lactate mediated by MCT-1 appears crucial to maintain axon 
function and survival [62].  Such axo-oligodendrocyte coupling may be particularly 
relevant when axons are energy-deprived [63].  
By definition, NAWM is difficult to characterize using conventional MRI techniques 
such as T1- or T2-weighted sequences. MRI studies have used non-conventional imaging 
methods to assess the chonology of diffuse WM changes and the impact these changes 
can have on disease and disability progression. These advanced techniques include 
diffusion tensor imaging (DTI), magnetization transfer imaging (MTI) or Proton 
Magnetic Resonance Spectroscopy (1H-MRS). Quantitative MRI studies have shown that 
diffuse WM changes are present from the early stages of the disease [64] and increase 
significantly over time. MRI studies have supported post-mortem evidence of NAWM 
damage occuring independently from focal damage [58] [65].  DAWM quantitative MRI 
measures, as reported by Vrenken et al., are intermediate between values of the NAWM 
and that of focal lesions [66]. 
MTI is a technique that is sensitive to microstructural changes in MS and its main 
metric, magnetization transfer ratio (MTR) is affected by myelin content and possibly 
axonal loss in post-mortem tissue [67].  Liu et al. found not only a significant decrease 
in MTR in the NAWM of MS patients compared to controls, but the authors were able to 
detect a clearly greater disease effect close to the ventricles [68]. It had already been 
shown that MS lesions are also more likely to occur around the ventricles [69]. Several 
factors could account for this pattern. Diffusion of CSF-mediated factors related to levels 
of meningeal inflammation has been suggested. CSF from MS patients has been shown 
to impair oligodendrocyte progenitor cells [70] as well as neuro-axonal function [71]. 
Decreased oxygen availability could also account for these findings as periventricular 
white matter is particularly prone to hypoperfusion in MS [72]. 
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Metabolic neuro-axonal function can be assessed in the MS WM by evaluating N-acetyl-
aspartate levels using Proton Magnetic Resonance Spectroscopy (1H-MRS). The extent 
of NAA reduction within the NAWM at the early stages of the disease was found to 
correlate with subsequent cognitive deficits [73]. These results echo similar findings 
using MTI [74] and support the concept of a disconnection syndrome as an underlying 
mechanism of cognitive disability in MS.  
PET imaging, using new tracers able to detect activated microglia and macrophages in 
vivo, has the potential to better our understanding of the role of diffuse microglial 
infiltration in disability progression. The translocator protein receptor (TSPO), a protein 
complex expressed by the outer mitochondrial membrane, is upregulated in activated 
microglial cells and macrophages, while maintaining low levels of expression in the 
brain parenchyma. These properties have encouraged the use of TSPO as a target for 
PET tracers. Compounds such as [11C]PK11195, [11C]PBR28 [75] or [18F]DPA714 [76] all 
bind specifically to the TSPO complex, with different levels of affinity. Studies 
conducted using [11C]PK11195 have found a significant increase in tracer uptake in 
widespread areas of periventricular and subcortical WM [77] suggesting diffuse 
infiltration by activated microglia at the SPMS stage of the disease. This technique was 
also able to detect the active inflammatory rim of chronic smoldering plaques. Giannetti 
et al. demonstrated the clinical significance of widespread microglial activation, showing 
that this phenomenon was detectable using PET with [11C]PK11195 in the NAWM of 
patients with CIS and more pronounced in those who later developed CDMS (figure 9) 
[78].  
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Figure 9: Normal appearing white matter on PK11195-PET images co-registered with MRI 
in three study subjects. The first subject is a healthy control (A) with PK11195 binding 
potential (BPND) in NAWM of 0.028; the second is a CIS subject without T2 MRI lesions 
(B), an EDSS score of 3.5 and PK11195 BPND in NAWM of 0.037; the third is a CIS subject 
with T2 MRI lesions (C), EDSS = 2.0 and PK11195 BPND in NAWM of 0.136. The color scale 
bar represents the BPND of PK11195. From Giannetti et al., Brain, 2015 [78]. 
 
 
2.2. Grey matter involvement 
 
As studies have been limited in their ability to correlate neurological disability to focal 
WM pathology, the focus shifted not only to diffuse WM abnormalities but also to the 
possibility of associated GM damage.  GM involvment in MS has perplexed scientists for 
many decades. Dawson’s question “Is then, the process that attacks the cortex different 
in its nature and origin from that which affects the rest of the central nervous system?” 
still resonates, though histopathological and neuroimaging studies have provided great 
insight into the nature, extent and chronology of GM pathology in MS.  
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2.2.1. Grey matter demyelination 
 
Unlike WM lesions, demyelination of cortical neurons is not visible macroscopically in 
post-mortem samples. In their seminal study, Brownell and Hughes (1962) [79] showed 
that about 22% of all brain lesions were located at least partly in the cerbral cortex and 
an additional 4% in the deep grey matter (DGM) structures. Improvement of 
immunocytochemical staining of myelin proteins has allowed more reliable 
investigation of GM demyelination, which has proven even more extensive than initially 
suspected. Recent pathological studies reported that the extent of GM demyelination 
often exceeds that of the WM in progressive patients [80], reaching up to 68% in 
extreme cases [58]. Grey matter demyelination is particularly extensive in the spinal 
cord, cerebellum, cingulate gyrus [80], thalamus [81] and hippocampus [82], regions 
that are of particular relevance to MS symptomatology, both physical and cognitive. 
Some have suggested that GM demyelination could, by impacting neuronal gene 
expression, reduce function in affected areas [82].  
Lesions found in the MS grey matter differ strikingly from their WM counterparts. 
Lymphocyte infiltration, complement deposition, and BBB disruption, all typical 
pathological hallmarks of WM lesions, are not usually found in cortical lesions (CLs). 
Different types of CLs (figure 10) have been described according to their location and 
extent and include: leukocortical, intracortical and subpial [83] [84]. Leukocortical 
lesions consist of WM lesions which extend into the GM. Intracortical lesions project 
along vessels within the cortical ribbon. Subpial lesions are bandlike plaques which 
extend from the pial surface into the cortical layer 3 or 4 and can involve several gyri. In 
DGM structures, lesions are more often mixed GM/WM lesions (about 60%) [81], 
whereas subpial lesions are more frequent at the cortical level. 
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Figure 10: Different types of cortical lesions in MS: leukocortical (a), intracortical (b) and 
subpial (c). (d) highlights the extensive nature of subpial demyelinating lesions which can 
extend over several gyri. From Calabrese et al., Nature Reviews Neuroscience, 2015 [85]. 
 
At the earliest stages of the disease, leukocortical lesions were found to be the most 
frequent and inflammatory in nature [86], with predominantly perivascular CD3+ and 
CD8+ T-cell infiltrates and less commonly B-cell infiltrates. These differ from cortical 
lesions found at the latter stages of the disease, which are more frequently subpial and 
less inflammatory. Whether inflammation is a prerequisite to GM demyelination still 
remains unsettled. 
It has been hypothesized that GM demyelination, and in particular subpial lesions,  
could be due to a myelinotoxic factor diffusing from the meninges. Subpial cortical 
lesions are often topographically related to mononuclear inflammatory infiltrates of the 
meninges in both early and late-stage MS [58] [86]. The presence of these meningeal B-
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cell follicles has been associated with more extensive cortical damage and a more severe 
disease course [87].  
The development of new MRI techniques sensitive to GM demyelination has allowed us 
to appreciate the clinical relevance of these lesions from the early stages of the disease. 
Sequences such as double-inversion recovery (DIR) or phase-sensitive inversion 
recovery have improved the detection of such lesions, and can be implemented on 
clinical grade scanners (figure 11). Although MRI techniques have become more 
sensitive to cortical demyelination, many cortical lesions remain undetected using MRI, 
especially with sequences available for routine practice. At 1.5T, only 18% of cortical 
lesions are detected when compared to histopathology [88] Higher field strength or 
combination of sequences can improve detection [89] [90] [91] [92]. Jonkman and 
colleagues recently reported that T2-weighted sequences at ultra-high field (7T) allowed 
prospective detection of 28% of cortical lesions [93]. Visualization of band-like subpial 
lesions still remains challenging [94] and availability of such techniques is currently 
limited. It is thus only the “tip of the iceberg” that can be seen and quantified using new 
MRI techniques [95]. But this “tip of the iceberg” still holds clinical significance. MRI 
measures of cortical demyelination have shown that GM lesions play an important role 
in physical and cognitive deficits (table 2). Cerebellar cortical lesion load also correlates 
with cerebellar function.  
The potential contribution of CLs to the diagnostic process was recently suggested by 
Filippi et al. [96]. The authors found that the presence of at least one CL on baseline 
DIR MRI improved the identification of patients with CIS at risk of converting to CDMS. 
The applicability of new criteria of DIS which would include the presence of CLs 
remains to be further explored, especially considering the high false positive detection of 
CLs [88] [93] despite established consensus scoring recommendations [97]. 
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Figure 11: Improved detection of intra-cortical lesions (white arrow) using phase sensitive 
inversion recovery (PSIR, left) in combination with double inversion recovery (DIR, 
middle), compared to conventional fluid attenuated inversion recovery (FLAIR, right). 
Images kindly shared by Dr Flavia Nelson, Associate Professor of Neurology at the 
University of Texas, Medical School at Houston. 
 
 
Study Patients Technique Findings 
Harrison et al., 
2015 [98] 
30 RRMS/ 6 SPMS 7T, MPRAGE and 
MPFlair 
- CL volume correlates with EDSS more 
robustly than WM lesions. 
- CLs also associated with cognitive 
performance 
Favaretto et al., 
2015 [99] 
10 CIS/ 24 RRMS/ 
6 SPMS 
3T, DIR and 
PSIR 
- Cerebellar CL number correlates with 
cerebellar clinical scores 
Harrison et al., 
2015 [100] 
28 RRMS/ 6 SPMS 7T, MPRAGE and 
MPFlair 
- Thalamic lesion burden correlates with 
EDSS scores 
Calabrese et al., 
2013 [39] 
334 RRMS 
 
1.5T, DIR - CLs one of three best predictors of 
conversion to SPMS at 5 years 
Papadopoulou et 
al., 2013 [101] 
65 CIS - RRMS/ 26 
SPMS - PPMS  
1.5T, DIR - CL volume correlates with cognitive 
outcome measures but does not 
independently predict cognitive status  
Calabrese et al., 
2013 [102] 
95 RRMS/ 45 
“benign” MS 
1.5T, DIR - Low CL burden associated with benign 
disease course 
Nelson et al., 
2011 [103] 
39 RRMS and 
SPMS 
3T, DIR, PSIR - Strong association between CLs and 
cognitive impairment 
Mike et al., 2011 
[104] 
20 RRMS, 6 SPMS 3T, 3D Flair and 
3D-IRSPGR 
- CL metrics correlate with EDSS scores 
and cognitive measures (SDMT and 
CVLT-II) 
 
Table 2: Selection of neuroimaging studies performed within the last 5 years that have 
assessed the clinical relevance of cortical lesions using MRI.   
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2.2.2. Neurodegeneration 
 
As we have seen previously, degenerative changes in axons within acute WM lesions or 
NAWM have been well documented. Postmortem studies have also provided evidence of 
early and evolutive neuronal pathology in the MS grey matter. Peterson and colleagues 
reported neuritic changes within cortical lesions described as axonal transections, 
dendritic transections and apoptotic loss of neurons [83]. Axonal loss in GM structures 
is associated with on-going inflammatory activity [83] [81]. Yet, axonal damage in active 
GM lesions remains much less extensive than in acute active WM lesions. Neuronal 
death on the other hand was seen in chronic lesions without significant inflammation, 
suggesting that this phenomenon was not directly linked to the immune insult but might 
be a consequence of chronic injury. Wegner et al. quantified neuronal damage in the MS 
neocortex. The authors found a 10% reduction in mean neuronal density in leukocortical 
lesions compared to normally myelinated cortex, with decrease in neuronal size and 
significant changes in neuronal shape [105] [106]. Synaptic loss was significant in 
lesional cortex and occurred in greater proportion than neuronal soma reduction (-50% 
synaptophysin signal), suggesting that loss of dendritic arborization is an important 
feature in MS [105]. Pathologic changes in neuronal morphology, as well as reduced 
neuron size and axonal loss were also detected in normal-appearing cortex compared to 
controls [105] [107]. Klaver et al. reported a 25.4% loss of NeuN-positive neurons, 
reduced axon density (-31.4%) and 11.4% smaller neurons  in type III cortical lesions 
(figure 12), while axonal density and neuronal size were also significantly reduced in the 
NAGM (-33.0% and -13.1% respectively) [108].  
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Figure 12: Neuronal loss in Type III cerebral cortical lesions in MS. Control (Ctrl) (A) and 
MS (B) sections immunostained for NeuN demonstrating overall neuronal loss in MS 
cortex. (C) Antimyelin PLP immunostained section from a patient with MS (B) showing 
subpial demyelination (original magnification: 100x). High-magnification pictures from 
cortical layer II (D, E), with matching pictures demonstrating the quality of segmentation 
scripts (F, G) (digital zoom from original magnification: 100x). From Klaver et al., J 
Neuropathol Exp Neurol, 2015 [108]. 
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Figure 13: Synaptic loss in demyelinated hippocampus. Confocal images of multiple 
sclerosis (MS) hippocampus immunostained with antibodies specific to MAP2 (red) and 
synaptophysin (green) show punctuate presynaptic terminals (green) surrounding 
neurons in CA1 (A, B) and dentate gyrus (C, D) regions in MS myelinated (A, C) and MS 
demyelinated (B, D) hippocampus. Compared to myelinated MS hippocampi, pre- synaptic 
terminals were significantly decreased (G) in demyelinated MS hippocampi. From Dutta et 
al., Annals of Neurology, 2011 [109]. 
 
 
The neurodegenerative changes seen in the MS cortex are more subtle than those 
described in DGM structures, particularly the thalamus. Cifelli and colleagues reported 
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a 23% reduction in mean neuronal density corresponding to a 35% loss of total neuronal 
numbers in the MS thalamus compared to controls [110]. Unlike neocortical structures, 
neuronal density was decreased in both demyelinated and non-demyelinated DGM 
compared to control DGM, though the loss of neurons may be more pronounced in 
demyelinated areas [81].  Neuronal atrophy and morphologic changes were also 
detected in the MS DGM regardless of myelination status and may precede or 
accompany neuronal loss. In the hippocampus, neuronal counts were decreased by up to 
30% depending on location [111]. Also in the hippocampus, Dutta et al. reported 
substantial reduction in synaptic density (figure 13) [109]. They found decreased 
expression of neuronal proteins involved in axonal transport, synaptic plasticity, and 
neuronal survival in demyelinated hippocampi as well as altered expression of neuronal 
miRNA [109] [82]. These findings may explain, at least partly, some of the cognitive 
deficits observed in MS patients.                                  
The mechanisms underlying neuronal pathology remain to be fully established. Of 
particular interest is the interplay between WM and GM pathology. At least at the late 
stage of the disease, which is more frequently explored by post-mortem studies, focal 
WM damage fails to correlate with neuronal changes in the GM [112] [113]. However 
recent neuroimaging studies demonstrated that focal WM pathology, at least in relevant 
locations, might impact MRI-driven GM atrophy measures at earlier stages of the 
disease [114] [115] [116].  It can also be suggested that loss of myelin and reduction in 
axonal density observed diffusely in the NAWM plays a role in the neurodegenerative 
process by promoting retrograde or trans-synaptic degeneration (figure 14). In support 
of this hypothesis, anatomical connection has been shown to influence the progression 
of neurodegeneration. Recent studies have provided evidence of neuronal dysfunction in 
connected GM neurons and correlated loss of integrity of WM tracts to histopathological 
measures of neurodegeneration in corresponding GM structures [112].  This was further 
supported by reports of tract-specific associations between cortical thinning patterns 
and MRI-derived metrics of NAWM integrity [117]. These findings suggest a link 
between diffuse damage of the WM and neurodegenerative processes in connected GM. 
Many however argue that WM pathology cannot satisfactorily explain the full extent of 
diffuse GM damage observed in MS, including pathological changes observed therein 
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[85]. Despite a clear degree of relationship, neuronal damage may also occur 
independently from WM pathology. 
 
         
Figure 14: Undisturbed neuronal connectivity (upper panel) can be impaired by retrograde 
degeneration (middle panel) propagating backwards in cortical neurons whose axons have 
been damages by WM lesions or along WM tracts. The WM tract damage can lead to 
microglial inflammation (middle panel) and retrograde neuronal cell death (lower panel), 
as well as anterograde Wallerian degeneration below the damage. From Calabrese, Nature 
Reviews Neuroscience, 2015 [85]. 
 
Neurodegenerative processes appear particularly prominent in certain types of GM 
demyelinated lesions. Local inflammation, microglial activation, or loss of trophic 
support from surrounding glia can all contribute to neurodegeneration within 
demyelinated lesions. However, neuronal changes in non-demyelinated areas have been 
reported both in the neocortex and in subcortical GM structures [105] [107] [108], 
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suggesting that focal GM demyelination and neurodegeneration are at least partly 
distinct phenomena in progressive MS.  
A number of studies have drawn attention to the inflammatory process occuring in the 
meningeal compartment. Meningeal inflammation is widespread and can be 
exacerbated by the presence of B-cell follicles in the meningeal space (figure 15) in a 
proportion of patients with progressive MS [87] [118]. These lymphoid structures 
appear to spatially coincide with subpial demyelinating lesions and were associated with 
quantitative increase in microglial activation within the GM [118]. SPMS cases with B-
cell follicles presented a more severe disease course, with younger age at onset, younger 
age at irreversible disability and earlier death, emphasizing the clinical significance of 
these findings [87]. Magliozzi et al. later demonstrated significant neuronal loss with a 
gradient away from the pial surface and more severe cortical thinning in SPMS patients 
characterized by B-cell follicle-like structures in the meninges [113]. The link between 
meningeal inflammation and GM damage is further corroborated by studies pointing to 
a specific role exerted by both meningeal T cells and activated microglia in diffuse 
axonal loss in the spinal cord [119]. These findings strengthen the hypothesis that 
meningeal inflammation is implicated in neurodegeneration in MS and contributes to 
clinical severity and progression.  
 
            
Figure 15: B-cell follicle-like structures in meningeal space of SPMS patient. (A, B) follicle 
of modest size. (C) Extensive infiltrate filling entire sulcus. From Howell et al. Brain, 2011 
[118].  
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Both inflammatory cells present in the meninges and activated microglia in the GM can 
induce the production of oxygen and nitric oxide (NO) species by enzymes including 
nicotinamide adenine dinucleotide phosphate oxidase [120]. This oxidative burst can 
lead to or further amplify mitochondrial dysfunction and energy failure which are 
increasingly being recognized as major pathways of neurodegeneration in MS [121] 
[122]. Neurons in MS GM exhibit decreased respiratory chain function and 
mitochondrial gene expression [123]. Furthermore, multiple clonally expanded deletion 
of neuronal mitochondrial DNA are found diffusely and irrespectively of lesions in the 
MS cortex [124]. Respiratory deficiency creates a mismatch between energy demand and 
ATP supply which is thought to drive neuronal dysfunction or degeneration via 
excessive stimulation of calcium-dependent degradative pathways [125].  
Sodium channel redistribution along denuded axons can aggravate this imbalance by 
significantly increasing energy demand in a context of supply deficit, leading to a state 
of “virtual hypoxia” [126]. Demyelinated axons are unable to maintain ionic balance 
between intracellular and extracellular space. Sodium channel influx triggers calcium 
cellular entry by reversing activity of Na+/Ca2+ exchangers, resulting in elevated intra-
axonal calcium levels. Increased Ca2+ concentration can be further exacerbated by 
injury-induced release of calcium from neuronal intracellular stores. Multiple 
degradation pathways are subsequently activated resulting in mitochondrial damage, 
activation of NO synthase, proteases and lipases which will contribute to neuronal injury 
[127].  
Iron stored within oligodendrocytes and myelin sheaths may be liberated following 
demyelination. In its extracellular form, iron generates reactive oxygen species and 
contributes actively to oxidative damage. Iron is absorbed by microglia and 
macrophages where it accumulates until these cells degenerate and cause a second 
oxidative burst upon liberation of their iron content in the extracellular space [128]. 
Iron may also accumulate in axonal processes and contribute along with extracellular 
iron to axonal and neuronal degeneration [129]. As iron physiologically accumulates in 
an age-dependent fashion with a plateau around age 40-50 , an amplification of neuro-
degenerative processes may be observed with age. 
Additional factors have been thought to contribute to the imbalance between energy 
supply and demand and to downstream neurodegeneration. Decrease in cerebral blood 
 48 
flow, thought to be mediated via release of vasoconstrictive peptides such as Endothelin-
1 (ET-1) by activated astrocytes [130], has been reported in MS patients evaluated by 
MRI from the early stages of the disease [131] [72] [132]. Cerebral hypoperfusion might 
play a role in certain lesion formation [133], axonal and neuronal damage and 
consequently in disability progression [134] [135]. Toxic exogenous factors such as free 
radicals and cyanates from smoking may further exacerbate mitochondrial dysfunction 
and oxidative stress-related mechanisms [136]. 
Glutamate excitotoxicity may also play a role in GM neuronal degeneration beyond 
acute inflammatory attacks. MS-related modifications of glutamate levels in specific GM 
regions have been reported using MR spectroscopy [137], though these findings were 
not confirmed by others [138]. 
 
In conclusion, many well-conducted studies of post-mortem tissue have shown that GM 
damage dominates the pathological process as MS progresses. These studies have 
demonstrated the clinical significance of the degenerative process occuring in the MS 
GM and underscored the need to understand its causes. Strong focus on the very early 
stages of the disease is necessary to determine the primary insult affecting the MS grey 
matter and longitudinal follow-up will shed light on the relationship between 
demyelination, inflammation and neurodegeneration at different stages of the disease. 
Such approach may not be feasible using post-mortem or biopsy tissue samples. 
Development of pathology-specific imaging techniques, in particular techniques able to 
assess specifically the neuronal compartment, are necessary to further our 
understanding of GM pathology in MS. They will also prove uniquely useful to monitor 
individual patients in the clinical setting or in the context of clinical trials focused on 
neuroprotective therapy.  
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Figure 16: Oxidative stress-related mechanisms of tissue injury in multiple sclerosis. (a) 
Microglia is activated by unknown trigger pathology, the breakdown of the blood-brain 
barrier, and local and systemic inflammatory stimuli. Microglia releases nitric monoxide 
and superoxide molecules into the extracellular space. Additional amplification 
mechanisms involve microglia preactivation via axonal degeneration (d). (b) Iron is 
physiologically stored within the myelin sheets and liberated into the extracellular space 
upon demyelination. Extracellular iron amplifies oxidative stress inducing the production 
of highly reactive hydroxyl radicals. Iron is absorbed by microglia, which show histological 
signs of cell death under the high iron load and thus may release iron and initiate a second 
wave of oxidative stress. (c) Mitochondrial DNA (mtDNA) is vulnerable to free radical-
mediated damage resulting in mtDNA deletions, which are found in neurons and axons of 
patients with multiple sclerosis. Mitochondria carrying such mutations are amplified by 
the clonal expansion in neurons. The mitochondrial respiratory chain is inhibited by 
covalent modifications caused by free radicals both competitively and irreversibly. A 
combination of these factors leads to energy failure via decreased ATP production. 
Exogenous factors, such as free radicals and cyanate delivered by smoking, inhibit 
mitochondrial function in experimental conditions. From Haider, Oxidative Medicine and 
Cellular Longevity, 2015 [128] 
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In vivo imaging techniques, in particular MRI, have had a major impact in MS. 
Detection of MS lesions on conventional acquisitions, such as T2- or T1-weighted 
sequences, has enabled earlier diagnosis of the disease and follow-up of subclinical 
inflammatory activity.  As the role of neurodegeneration in MS pathogenesis and 
disability progression is clearly established, new treatments that could slow, halt or 
reverse this process are now being proposed. Unfortunately classic MRI measures of 
disease activity do not inform on the neurodegenerative process and we are witnessing a 
shift in imaging targets, from inflammation and demyelination to neurodegeneration 
[139] [140].  
 
 
1. GREY MATTER ATROPHY 
 
The cortex represents 65% of brain parenchymal tissue and GM largely drives the 
atrophic process occuring in MS. GM volume can be measured on conventional MRI 
sequences with freely available tools among which the most commonly used are FSL 
(http://fsl.fmrib.ox.ac.uk/fsl/fslwiki/), FreeSurfer (http://freesurfer.net) and SPM 
(http://www.fil.ion.ucl.ac.uk/spm/). This has tremendously helped the field in 
understanding the occurrence and chronology of GM tissue loss, as total and regional 
GM volumes, as well as cortical thickness can be assessed (Figure 17). MS lesions tend to 
be recognized as GM by the different softwares used in research, a misclassification that 
may affect GM volume estimation and obscure disease-mediated volume changes. This 
is why a procedure, called “lesion inpainting” is generally applied before GM 
segmentation. This procedure replaces lesional voxels with values approximating 
NAWM intensity [141].  It has been shown to significanly improve accuracy of GM 
volume and cortical thickness estimation.  
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Figure 17: Example of FreeSurfer for GM volume and cortical thickness estimation. After a 
first step of WM lesion segmentation, a procedure of lesion inpainting is used to limit 
misclassification of WM lesions as GM. Then the volumetric pipeline can be used for 
estimation of global or regional GM volumes and region-of-interest (ROI) analyses. The 
surface reconstruction pipeline allows estimation of cortical thickness. 
 
 
At the group level, GM atrophy can be seen from the first clinical event as loss of GM 
volume or cortical thinning [142] [143] [144]. Topographically, GM atrophy is most 
evident in the DGM structures such as the thalami, hippocampi, and in the cerebellum 
[145] [146] at the early stages of the disease. It later extends to neocortical structures 
and becomes widespread as MS progresses, clearly dominating the disease process in 
the later stages.  
Interestingly, GM atrophy doesn’t follow the same dynamic pattern of accrual as WM 
atrophy. In a longitudinal study over 4 years, Fisher and colleagues demonstrated that 
GM atrophy increases with disease stage from CIS to SPMS while WM tissue loss 
remained constant [147]. Rocca et al. also reported that GM and WM damage followed 
different trajectories in the first 2 years after CIS [143], suggesting that these 2 events 
may be at least partly independent.  
In CIS patients, GM volume loss can predict conversion to CDMS, and shorter time to 
second attack [144] [148]. GM volume has emerged as a clinically relevant measure with 
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strong relation to disability progression. Many studies have shown that GM volume 
correlates with measures of physical and cognitive disability in cross-sectional as well as 
longitudinal cohorts [147] [149] [150] [151] [152]. GM atrophy has been shown to be 
more useful than WM atrophy in prediction models of future disability and is therefore 
regarded as a valuable outcome measure in clinical drug trials [153]. 
Unfortunately this measure is inherently non-specific and could be explained by the 
different processes taking place within the GM such as demyelination, glial pathology or 
neuronal damage. Postmortem studies have tried shedding light on the issue. Wegner 
and colleagues have shown that cortical thinning can occur within or outside lesions and 
is not related to the extent of cortical focal demyelination [105]. Recently, Popescu et al. 
confirmed that in non-lesional neocortex, cortical volume was not related to myelin 
density [107]. This was later supported by another study using different sampling 
techniques [154]. These observations suggest that demyelination is not the primary 
substrate of volumetric loss and cortical thinning. In contrast, significant correlations 
were found with neuronal density, neuronal size and axonal density indicating that, at 
the later stages of the disease, MRI-measured GM atrophy is driven by the 
neurodegenerative process.  
There are several limitations however to the use of GM atrophy as a sensitive marker of 
neuronal damage in MS. First, measures of GM atrophy or cortical thinning do not 
reflect the entire spectrum of neurodegenerative changes occuring within the MS GM. 
Several studies have shown significant alterations in synaptic density or dendritic 
arborization in animal models of the disease [155], as well as in the MS neocortex [83] 
[105]. These changes are also particularly significant in the hippocampus. Dutta and 
colleagues reported decreased hippocampal neuronal gene expression, in particular 
KIF1A, which is involved in anterograde transport of synaptic vesicles to the presynaptic 
terminal. They found evidence of synaptic pruning even in the absence of significant 
neuronal loss and postulated that such changes could underlie the cognitive 
disturbances experienced by MS patients [109] [156]. Michailidou et al. recently 
confirmed the extent of synaptic pathology of the MS hippocampus [157], while 
Novkovic et al. related memory deficits to impairment of synaptic plasticity in 
experimental autoimmune encephalomyelitis (EAE), a common animal model of MS 
[158]. These findings clearly support the clinical significance of subtle changes in 
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synaptic density or dendritic arborization occurring in the GM. The changes remain 
nonetheless undetected by GM atrophy measures [107]. 
Another potential issue is that volumetric measurements may be influenced by water 
content, extracellular matrix, and inflammatory infiltration. Several studies reported 
robust changes in brain volumes between dehydrated and rehydrated states [159] [160]. 
A volume change of about 0.36% during the dehydration-rehydration interval is well 
above previously reported scan-rescan reproducibility errors and close to a recently 
proposed pathological “cut-off” for volume loss of 0.4% [161]. Furthermore, it can be a 
complicated task to distinguish true atrophy from “pseudoatrophy”, a significant loss of 
brain volume, which may occur after initiation of anti-inflammatory therapy, and a 
phenomenon that is not yet fully understood [162].  
 
 
2. QUANTITATIVE MRI 
 
2.1. Diffusion Tensor Imaging 
 
Diffusion denotes the random motion of molecules, also called Brownian motion. Water 
is the most convenient molecular species to study with diffusion MRI, though other 
metabolites may also be studied. Water molecules move in the brain and interact with 
many tissue components such as cellular or subcellular membranes or organelles. The 
distribution of motion of water molecules thus provides clues to the structure and 
organization of brain tissue. Molecular motion may not be the same in all directions, a 
phenomenon called anisotropy. Diffusion-weighted MRI only characterizes a single 
parameter, the diffusion coefficient D. Diffusion tensor imaging (DTI) is used to map 
and characterize the three-dimensional diffusion of water as a function of spatial 
location (figure 18). The diffusion tensor describes the magnitude, the degree of 
anisotropy, and the orientation of diffusion anisotropy. Consequently, the diffusion 
tensor is thought to be a sensitive marker for characterizing both normal and abnormal 
tissue microstructure [163]. It has been proposed recently as a way to assess GM 
integrity. The interpretation of diffusion tensor is complex. Common DTI metrics used 
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in MS are fractional anisotropy (FA), which reflect the prevalence of diffusivity along 
one direction, or Mean Diffusivity (MD) a measure of global water diffusion.  
 
          
Figure 18: Diffusion Tensor Imaging. (A) Representation of an elliptical tensor with 3 main 
axes. The longest axis is the primary eigenvector (λ1) and reflects the diffusion parallel to 
fibers (“axial” diffusivity). The other two axes are the second (λ2) and third (λ3) 
eigenvectors, whose average provides a measure of “radial” or perpendicular diffusivity. 
(B) DTI color map allows visualization of direction information about diffusion by color-
coding direction information from the eigenvectors. 
 
 
Progressive and widespread DTI alterations have been demonstrated in the MS GM, 
though these changes have shown conflicting directionality depending on the study. MD 
consistently increases across studies, while FA has been found to either decrease or 
increase. The discrepancy has been explained by possible differences in GM 
inflammation [164]. Increased FA and MD values have been reported in deep grey 
matter structures [165] or cortical NAGM and lesions [166] in RRMS and CIS. 
Decreased FA values were also found in similar structures and populations of MS 
patients [167] [168] [169]. Nonetheless, from a clinical point of view, DTI metrics are 
attractive. There is mounting evidence that DTI-detectable changes of the GM are more 
severe in disabling forms of MS [170]. Several authors reported significant correlations 
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between GM FA or MD and measures of clinical disability such as EDSS or the MS 
functional composite score (MSFC) [168] [166]. In a study by Yaldizli and colleagues, 
cognitive disability evaluated by the symbol digit modalities test (SDMT) correlated with 
DTI measures in non-lesional cortical GM, though the correlation didn’t remain in a 
multivariate model including other MRI-derived metrics [167]. Using long-term follow-
up, Rovaris et al. were able to demonstrate that GM DTI features could independently 
contribute to the identification of PPMS patients at risk of progression [171].  
DTI findings reported by MS studies are often attributed to axonal degeneration and 
fiber transection [165] or microglial activation [166]. Local inflammation levels can also 
confound DTI measurements. Given the paucity of postmortem studies combining DTI 
and pathological analyses [172], current interpretation of DTI findings is far from 
definitive. Some have proposed measurements of “axial” diffusivity (the principal 
eigenvalue of the diffusion tensor) and “radial” diffusivity (the average of the second and 
third eigenvalues), which have been interpreted as axonal degeneration and 
demyelination respectively [173], though this claim was later found speculative at best 
[174]. More recently, different modeling techniques of diffusion-weighted MRI data 
have been proposed to try to better capture the relative contribution of neuronal 
damage, demyelination and inflammation to GM pathology [175] [176]. Their relevance 
and applicability in MS remain to be established.  
For the reasons cited above, DTI appears to be a sensitive yet non-specific marker of GM 
damage in MS. This observation along with the difficulties associated with image noise, 
echo planar imaging (EPI)-induced distortions and partial volume averaging in large 
voxels, challenge the application of DTI measurements for diagnostic or prognostic 
purposes at the individual level in MS.  
 
 
2.2. Magnetization Transfer Imaging (MTI) 
 
MTI is a MRI technique that generates contrast based on the phenomenon of 
magnetization exchange between the unbound protons in free water and the protons 
bound to macromolecules. Changes in magnetization transfer ratio (MTR, which reflects 
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the exchange rate of magnetisation transfer between the two proton pools) have been 
detected in both MS WM [177] [66] [178] [179] and GM [180] [181] [182]. 
Using voxel-based techniques, it was shown that GM MTR reduction affects 
predominantly the DGM structures in the early stages of the disease, and the cortex 
during the progressive phase [182]. Filippi et al. reported that GM MTR was an 
independent variable associated with cognitive deterioration over a 13-year follow-up 
period [181]. This was further confirmed in PPMS patients [183]. Crespy et al. suggested 
that analysis of GM MTR maps could provide insights into individual GM pathology 
[180].  
Though sensitive to microstructural changes in the MS GM, MTI metrics are not 
thought to reflect changes within the neuronal compartment. Histopathological studies 
have instead suggested that MTR is sensitive to demyelination in the WM [67], as well 
as in the GM [184] [185]. Yaldizli et al. later reported that MTR measures were indeed 
significantly lower in DIR-visible cortical lesions compared to non-lesional cortex [167]. 
Derashkhan and colleagues have proposed surface-based analyses of MTR cortical 
changes as a plausible method to quantify subpial demyelination, which remains hard to 
detect using DIR [186].  
    
 
2.3. Proton Magnetic Resonance Spectroscopy 
 
Proton Magnetic Resonance Spectroscopy (1H-MRS) allows quantification of different 
metabolites in brain tissues (figure 19). It can be used to measure levels of N-acetyl 
Aspartate (NAA), a metabolite long recognized as an indicator of neuronal and axonal 
function. Based on immunohistochemical findings NAA is present in most neuronal cell 
populations, but the intracellular concentration appears to vary greatly between 
neuronal groups [187]. After synthesis by mitochondria, NAA is exported to the 
neuronal cytoplasm, where it remains present in high concentration [188]. Its function 
has yet to be fully established.  
NAA levels can be measured using 1H-MRS either within small volumes (single voxel 1H-
MRS, figure 14) or across larger areas (Chemical Shift Imaging, CSI). Hunter’s angle, 
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drawn from the myoinositol peak to NAA peak is a visual way to assess normality of the 
NAA spectrum. It normally averages 45° from the x-axis. NAA or other metabolite 
concentrations are usually expressed as a ratio (relative quantification) rather than as 
absolute concentrations. In relative quantification, one metabolite peak is used as the 
concentration standard. A classic example is the ratio NAA/ Creatine. One of the 
limitations of such quantification method is that changes in the ratio can reflect changes 
in the concentration of the numerator, the denominator, or both and are usually more 
difficult to interpret than absolute concentrations.  
 
 
 
Figure 19: 1H-MRS. Left: representative proton MRS spectrum of normal human brain with 
major peaks of interest depicted. Hunter’s angle is represented in red. From Moffett et al. 
Progress in Neurobiology, 2007 [187]. Right: single voxel acquisition on posterior cingulate 
gyrus. From Pokryszko-Dragan et al., Journal of the Neurological Sciences, 2014 [189]. 
 
NAA levels have been found to be reduced by 10-20% on average in the thalamus of 
RRMS patients compared to controls [110] [190]. Geurts and colleagues also reported 
significant decrease in thalamic NAA in PPMS patients [191]. Lower NAA/Cr values 
were found in the posterior cingulate gyrus of RRMS patients when compared to 
controls in one study [189]. Though other groups were unable to detect similar 
metabolic changes in the cortical grey matter [191] [192] [193] [73].  
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A reduction in NAA levels can occur in case of neuronal loss or damage but can also 
reflect reversible metabolic dysfunction affecting the mitochondria. Histopathological 
studies have demonstrated robust correlations between NAA levels and axonal 
pathology [194]. Although MRS provides unique and specific metabolic information 
regarding neuronal function and viability, several factors have limited its utility. Among 
these limitations, the necessary sampling over large voxels, poor spatial resolution, and 
susceptibility artifacts in regions close to bone may explain why MRS has not been more 
widely used to assess GM and in particular cortical damage in MS, although this 
technique has been available for many years. 
 
 
3. POSITRON EMISSION TOMOGRAPHY  
 
3.1. Principles of PET imaging 
 
A PET scanner is an imaging system that provides analytical tomographic 
measurements of the tissue concentration of compounds labeled with a positron 
emitting radionuclide (figure 20). Only minimal or ‘‘tracer doses’’ of neuroreceptor 
radiotracers need to be injected to estimate receptor parameters. After injection, the 
study subject is placed within the field of view (FOV) of the scanner where several 
detectors can register incident gamma rays. The radionuclide decays and emits 
positrons, which then annihilate with an electron to produce two 511 keV gamma rays. 
The gamma rays are emitted in opposite directions at approximately 180 degrees from 
each other and can be detected by the scanner’s detectors. The annihilation event is 
usually very close to the site of positron emission because the emitted positrons rapidly 
lose their energy in tissue. The distance the positrons travel before annihilation is small, 
typically less than 2 mm. The detectors are connected with fast timing circuits that look 
for two simultaneous or “coincident” events on opposite sides of the head. Detection of 
the two coincident gamma rays defines a line, which intersects the position of the 
annihilation event. These "coincidence events" can be stored in arrays corresponding to 
projections through the patient. The raw data collected by the PET scanner is then 
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mathematically reconstructed to produce tomographic images of tissue radioactivity 
concentration. Coregistration of MRI and PET data enables the interpretation of 
functional data with localizing high-resolution structural information. 
 
 
Figure 20: Principles of PET imaging. From Dr Mirwais Wardak, Brain Imaging with 
Positron Emission Tomography: Quantification and Biomedical Applications in 
Alzheimer’s Disease and Brain Tumors, UCLA, 2013. 
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3.2. [18F]-fluorodeoxyglucose (FDG) PET and 
neuronal metabolism 
 
Glucose is the brain’s main substrate for energy supply. Experimental studies have 
shown that glucose consumption closely reflects neuronal function in the healthy brain 
[195]. PET with [18F]FDG can estimate the metabolic rate of glucose (CMRglc) because 
the tracer is taken up by brain tissue and phosphorylated like glucose. Typical resting 
state CMRglc values are in the range of 40 to 60 μmol glucose/100 g/min in the GM and 
around 15 μmol glucose/100 g/min in WM [196]. In diseases impairing neuronal 
function, significant reduction in CMRglc may be seen. 
In MS, global reduction in brain CMRglc has been reported by Pozzilli et al. [197].  
Bakshi et al. quantified a 9% reduction in brain glucose metabolism in MS patients 
compared to controls, with dramatic absolute reduction in the superior mesial frontal 
cortex, superior dorsolateral frontal cortex, mesial occipital cortex, lateral occipital 
cortex, deep inferior parietal white matter, and pons [198]. Longitudinal follow-up of 10 
MS patients showed that brain glucose metabolism decreases over time with the most 
pronounced reductions of CMRglc detected in frontal and parietal cortices [199]. 
Reduction in regional or global CMRglc correlates with measures of cognitive disability 
[200] and fatigue [201].  
Nonetheless, the interpretation of [18F]FDG PET is not straightforward in an 
inflammatory disorder such as MS, as measures of glucose metabolism may be 
artificially increased by local inflammation and glucose uptake by inflammatory cells 
[202] [203].  
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3.3. Flumazenil, an antagonist of the central 
benzodiazepine receptor 
 
3.3.1. Properties 
 
Flumazenil (FMZ) is an antagonist of the central benzodiazepine (BZD) receptor, a 
component of the ubiquitous GABAA receptor complex. GABAA receptors are pentameric 
channel receptors permeable to chloride ions and belong to the family of Cys-loop 
ligand-gated ion channels along with glycine receptors, serotonin type 3 receptors and 
nicotinic acetylcholine receptors. GABAA receptors are present on axo-somatic and axo-
dendritic synapses on neurons throughout the cortical and subcortical GM [204]. BZD 
receptors are allosteric modulatory sites on GABAA receptors. Flumazenil binds with 
high affinity to BZD receptors containing the α1, α2, α3, or α5 subunits and less so to 
those containing α4 or α6 subunits.  
Initially [3H]FMZ for in vitro and ex vivo autoradiography, subsequently radiolabeled 
FMZ conjugates were developed for in vivo clinical studies with PET. In vivo [11C]FMZ 
PET was found to strongly correlate with [3H]FMZ autoradiography in hippocampal 
sclerosis [205]. [11C]FMZ is rapidly metabolized in vivo and exhibits high uptake in GM 
with retention of radioactivity in BZD receptor-rich regions, such as the cerebral cortex 
[206]. [11C]FMZ has several properties making it a useful PET tracer, including no 
metabolism in the brain, metabolites that do not cross the BBB, appropriate kinetics, 
and low nonspecific binding [207]. 
 
3.3.2. PET with [11C]FMZ in neurological disorders 
 
GABAA receptor density measured in vivo by PET with [
11C]FMZ has been reported as a 
specific marker of neuronal integrity and has allowed, over the past 15 years, to estimate 
neuronal damage in several neurological and psychiatric disorders.  
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Heiss et al. demonstrated that PET with [11C]FMZ combined with measures of cerebral 
blood flow could distinguish between irreversibly damaged and viable penumbra tissue 
[208] [209]. Pascual et al. reported decreased [11C]FMZ binding in the hippocampi and 
posterior cingulate gyri of patients with Alzheimer’s disease [210]. [11C]FMZ binding 
was decreased precisely in the regions showing the greatest degree of neuronal loss in 
post-mortem studies of early Alzheimer's disease. In addition, [11C]FMZ hippocampal 
binding correlated with memory performance. In major depression, decreased binding 
was found in the limbic parahippocampal and right temporal cortical areas. In the 
temporal area, [11C]FMZ binding showed a strong inverse correlation with 
hypothalamic-pituitary-adrenal axis activity [211]. A study using a related tracer 
[123I]iomazenil in Huntington’s disease found a 31% decrease in volume of distribution 
in the striatum of patients compared to age-matched controls [212]. This change was 
attributed to loss of binding sites and consequently synapses in these areas. No 
significant changes in cortical binding were found in these mildly to moderately affected 
patients. The authors also found strong correlations between [123I]iomazenil binding 
and clinical functional scores. In epilepsy, PET with [11C]FMZ can be acquired during 
the interictal period. Several studies have evaluated the clinical utility of [11C]FMZ PET 
in patients with MRI-negative focal epilepsy. [11C]FMZ PET helped identify surgically 
relevant abnormalities in about 50% of subjects [207]. The added value of FMZ PET 
compared to FDG in the context of epilepsy remains however unproven [213].  
 
 
3.3.3.  The Partial Saturation Method, a non invasive 
quantification technique 
 
Despite promising findings, the more widespread application of [11C]FMZ PET in the 
research or clinical setting has been limited by highly invasive modeling methods. 
Standard modeling protocols require serial arterial blood sampling for plasma input 
function to fit compartmental models. Arterial lines can cause complications such as 
hematoma, bleeding, and thrombosis and require local anesthetic administration. Other 
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modeling techniques have been proposed to analyze PET data without arterial input 
function. The simplified reference tissue model [214] model is applicable if a “true” 
reference tissue exists in which no specific binding of the radioligand occurs. It allows 
only measurements of the binding potential (BP) which is a combined measure of 
density of available neuroreceptors (Bmax) and affinity of the ligand to that receptor 
(Kd). Though proper quantification of changes in receptor density (Bmax) might be 
important to understand the pathophysiology of neurological disorders. 
Some investigators have proposed using Scatchard analysis, a common in vitro method 
based on the equilibrium relation: 
 
B/F= (Bmax-B)/KdVR 
 
With:  B= bound ligand concentration 
 F= free ligand concentration 
 Bmax= BZD receptor density 
 Kd= receptor-ligand affinity 
VR= reaction volume 
 
The plot of B/F vs B gives a straight line whose slope is equal to the inverse of the 
apparent equilibrium dissociation constant (KdVR) and whose intercept with the B axis 
gives the receptor density Bmax (figure 21, red line).  
Using Scatchard analyses eliminates the need for arterial blood sampling but requires 
separate estimation of bound and free ligand concentrations, as PET data will provide 
only a sum of these two components. Delforge et al. showed that bound ligand 
concentration decreases significantly over the usual duration of an experiment after 
FMZ injection with an average dose between tracer dose and saturation dose [215]. The 
partial saturation protocol [216] is based on this observation and allows estimation of 
BZD receptor density and receptor-ligand affinity from a single-injection experiment, 
without arterial blood sampling.  
The protocol consists of a coinjection of a [11C]FMZ tracer dose (about 20 mCi) and of a 
unlabeled FMZ partial-saturation dose (between a tracer dose and a saturation dose) 
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[216]. The choice of the unlabeled FMZ amount is important because it must be 
sufficiently large to occupy a significant percentage of receptor sites (at least 50% but 
preferably 70%) but not too large to observe a significant decrease of this percentage 
during the limited duration of the experiment (1 h at most). Data are analyzed using the 
usual Scatchard plot (figure 21-blue line). The free-ligand concentration F, assumed to 
be identical in all regions, is estimated from the pons. The pons was initially thought to 
devoid of BZD receptor sites but was later found to have small but not negligible BZD 
receptor concentrations (~4.7 pmol/mL) [216]. The percentage of PET-measured ligand 
concentration in the pons, which corresponds to the ligand bound to the pons receptor 
sites, can however be estimated as a function of time and of the injected FMZ dose. This 
curve may then be used in experiments to estimate the free ligand concentration F from 
the PET-measured pons concentration. The bound ligand concentration B in any region 
is then obtained by subtracting the free ligand concentration F from the PET-measured 
concentration. Assuming constant FMZ affinity, parametric images of the Bmax can be 
obtained [217], which map BZD concentration at each voxel (figure 22). 
 
                             
Figure 21:  Scatchard curve (red) and estimation from PET examination using the partial 
saturation method (blue) 
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Figure 22: Parametric images of the [
11
C]FMZ Bmax from a single experiment on a High 
Resolution Research Tomograph (HRRT, left) with corresponding MRI (right) at 
subtentorial level (top and middle) and infratentorial level (bottom).  
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1. SPECIFIC AIMS OF THE STUDY 
 
MS has long been regarded as an inflammatory demyelinating disorder of the WM. But 
post-mortem studies have recently shed light on the extensive involvement of the GM 
and its role in disability progression in MS. Neuronal damage, characterized by synaptic 
and dendritic loss as well as neuronal apoptosis, is thought to be a major substrate of 
clinical and in particular cognitive deterioration. Measurement of GM atrophy by MRI 
represents an interesting prognosis marker for long-term progression. While it appears 
to be driven by late neuronal loss, it may not capture the entire spectrum of 
neurodegenerative changes occurring in the GM especially at the early stages of MS. 
Therefore there is a crucial need for the development of imaging techniques, aimed at 
visualizing and quantifying neuronal damage in MS.  
 
GABAA receptor density measured in vivo by PET with [
11C]FMZ has been reported as a 
specific marker of neuronal integrity and has allowed to estimate neuronal damage in 
several neurological and psychiatric disorders. We hypothesized that this technique 
could provide insights into the extent of neuronal pathology in MS patients.  
 
The aims of this pilot study are as follow: 
- To quantify neuronal damage with [11C]FMZ PET at different stages of the 
disease using a non-invasive quantification method.  
- To investigate the relationship between neuronal injury and macroscopic WM 
damage. 
- To assess the clinical significance of this technique by determining the correlation 
between [11C]FMZ PET metrics and measures of physical and cognitive 
performance.  
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2. MATERIAL AND METHODS 
 
This study was approved by the local Ethics committee. All subjects gave written 
consent for participation. 
 
2.1. Subjects  
 
A total of 10 healthy volunteers and 20 MS patients were initially included in the study.  
 
Inclusion criteria for MS patients were as follow: 
- Patients had a diagnosis of MS according to McDonald et al. [14] 
- Either a relapsing-remitting course and EDSS < 4.0 (n=10) or a secondary 
progressive course and EDSS ≥ 4.0 (n=10) 
- Able to understand the objectives of the study 
- Able to give written consent 
 
All subjects were free from steroids, cyclophosphamide or mitoxantrone treatment for at 
least 1 month, and from benzodiazepines or medications known to interact with the BZD 
receptor for at least 15 days before inclusion in the study.  
 
Inclusion criteria for healthy volunteers were: 
- No history of neurological illness 
- Able to understand the objectives of the study 
- Able to give written consent  
- No abnormalities on brain MRI suggestive of on-going neurological disorder 
 
Women that were childbearing or breastfeeding were excluded. All females were advised 
to use an efficient contraceptive method and a plasmatic pregnancy test was performed 
before each PET examination.  
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One healthy volunteer showed incidental abnormalities on MRI suggestive of small 
vessel disease, one volunteer and one SPMS patient withdrew their consent before the 
end of the study and one RRMS subject failed to complete the MRI exam. Therefore the 
final population analyzed comprised 8 healthy volunteers and 18 subjects with MS (9 
RRMS and 9 SPMS).  
 
 
2.2. Clinical Evaluation 
 
Neurological and neuropsychological assessments were performed at time of MR 
imaging.  
 
Physical disability was evaluated using: 
- The Expanded Disability Status Scale (EDSS, Annex A)  
- The 25ft timed walk (25-FW) and 9-hole peg test (9-HPT), as part of the Multiple 
Sclerosis Functional Composite score (MSFC). 
 
Each subject also underwent short neuropsychological evaluation, which included: 
- Paced Auditory Serial Addition Test 3 seconds (PASAT-3), also part of the MSFC, to 
assess attention, working memory and speed of information processing,  
- Mini Mental State Examination (MMSE) a general scale sensitive to cortical 
degeneration 
- Rey-Osterrieth Complex Figure Test to evaluate visuospatial processing [218] [219] 
- Stroop Test to evaluate executive functioning [220] 
 
 
2.3. Magnetic Resonance Imaging Data Acquisition 
 
MRI was acquired on the same day as the clinical visit. 
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MRI was obtained for all participants on the same 1.5T Signa scanner (General Electrics 
Medical Systems) including: 
 
1) 3D- Fast Spoiled Gradient Recalled Echo (FSPGR) T1-weighted: TE= 2.2, TI=600, 
TR= 3000 ms, FOV= 240x260 mm, matrix 192x256, slice thickness:1.3 mm 124 slices;  
2) 2D- T2 weighted (FSE): TR=2920, TE=103, FOV=240x260 mm,  slice thickness=4.0 
mm, matrix 256x160;  
3) 2D- Fast fluid attenuated inversion recovery (FLAIR) TR=8002, TE=152, FOV=240 
mm, slice thickness=4.0 mm, matrix 256x256. 
 
 
2.4. PET acquisition and quantification 
 
PET imaging was acquired within 15 days of clinical and MRI examination. All subjects 
underwent PET with [11C]FMZ on a High Resolution Research Positron Tomograph 
(HRRT, Siemens Medical Solution, spatial resolution= 2.5 mm), providing 110 slices of 
1.1 mm thickness covering the whole brain (Annex B). 
 
Ready-to-inject, >99% radiochemically pure [11C]FMZ (ethyl 8-fluoro-5-[11C]methyl-6-oxo-
5,6-dihydro-4H-benzo[f]imidazo[1,5-a][1,4]diazepine-3-carboxylate or [11C]Ro151788) was 
prepared from cyclotron-produced [11C]carbon dioxide (Cyclone-18/9 cyclotron, IBA) 
using a commercially available TRACERLabTM FX-C synthesizer (General Electrics 
Medical Systems), and based on a process which was formerly performed on a home-
made modular system [221].  
 
Participants were positioned in the tomograph with their head maintained using an 
individually molded headholder. A 6 min brain transmission scan was performed before 
injection of the radioligand with a 137-Cs point source to correct the emission scan for 
tissue attenuations. Protocol consisted of a co-injection of carbon-11-labeled FMZ (285 
± 59 MBq) and unlabeled FMZ (10 µg/kg, Anexate ®) in order to partially saturate the 
BZD receptors. Twelve 3D frames of the entire brain of 5 min each were reconstructed 
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with an accelerated list-mode ordinary Poisson ordered-subset expectation 
maximization (OP-OSEM) algorithm to lower statistical noise at the voxel level without 
degrading spatial resolution [222]. The partial saturation protocol [215-217] was used to 
estimate the BZD receptor concentration (Bmax) for each voxel and voxel-based 
parametric images of the [11C]FMZ Bmax were computed using an in-house software.  
 
 
 
 
Figure 23: Study visits and steps from inclusion to image processing. 
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2.5. Processing 
 
Processing steps are summarized in figure 24. 
 
2.5.1. WM lesion segmentation and inpainting 
 
Using a semi-automated segmentation technique based on local thresholding (Jim 
version 3, Xinapse Systems, UK, http://www.xinapse.com), MS lesions were delineated 
by a single experienced observer on the 2D-T2 images using the coregistered 
information from FLAIR images. WM T2 lesion volume was calculated based on the T2 
lesion masks provided by Jim Software, then normalized for headsize of each subject.  
 
Prior to the inpainting process, lesions were also segmented on 3D-FSPGR images in the 
native space using the coregistered information from T2-weighted and FLAIR images. 
We then applied an automated inpainting technique that replaces lesional voxels with 
values derived from the intensity distribution of the white matter outside of lesions 
[141]. 
 
 
2.5.2. Grey matter segmentation and parcellation 
 
Cortical surface reconstruction and volumetric segmentation were performed using the 
“inpainted” 3D-FSPGR volumes with the Freesurfer v5.1.0 image analysis suite, 
(http://surfer.nmr.mgh.harvard.edu/). The technical details of these procedures are 
described in prior publications [223-226]. The segmentation of GM volumes and of the 
GM/WM interface for each subject was inspected and reprocessed after manual or 
automatic adjustments if errors were found.  
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2.5.3. Registration 
 
The parametric images of [11C]FMZ Bmax were registered to 3D-FSPGR images using a 
boundary-based registration method [227]. We visually checked all subjects to assess 
proper registration. 
 
 
2.5.4. Volume of interest (VOI) analyses 
 
Freesurfer segmentation and cortical parcellation with the Desikan-Killiani atlas label 
over 50 separate brain structures (Annex C).  
Results for total GM (TGM), cortical GM (CGM), lobar GM (frontal, cingulate, parietal, 
temporal, occipital and insula) and subcortical GM (thalamus proper, caudate, 
pallidum, putamen, hippocampus and amygdala) are presented here.  
In the cortical GM, we calculated the mean thickness of each lobe as well as the mean 
global cortical thickness. 
 The volume of each subcortical GM structure was calculated from the 3D-FSPGR 
images and normalized for head size.  
For each volume of interest, we calculated the mean Bmax, or density of BZD receptors, 
as well as the total amount of [11C]FMZ binding sites defined as the product of the Bmax 
by the total volume of the structure, then normalized by head size.  
 
 
2.5.5. Surface based analyses 
 
As the cortical thickness can vary substantially throughout the cortex, PET signal was 
registered on each individual surface and mapped along the midline of the cortical 
ribbon. Signal was then smoothed along the surface using a 2D 10 mm full width at half 
maximum (FWHM) Gaussian kernel. Data were then registered for all subjects to a 
surface template using FreeSurfer.  
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Figure 24: Processing pipeline of PET and MRI data. 
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2.6. Statistical analyses 
 
Statistical analyses were performed using the R Statistics software version 2.15.2 
(http://www.r-project.org/) and Matlab version R2014b (www.mathworks.com). 
Comparisons of demographic and clinical variables were done using the Mann-Whitney 
U test for quantitative data.  
 
For volume of interest analysis, the following metrics were analyzed:  
- Volume normalized by head size (volume fraction)  
- Regional and global cortical thickness 
- [11C]FMZ Bmax  
- Total amount of [11C]-FMZ binding sites normalized by head size.  
 
Comparisons between MS patients and healthy controls were performed using linear 
regression analyses adjusting for the effect of age and sex with a significance threshold 
of p<0.05. Exploratory subgroup comparisons of imaging data between RRMS, SPMS 
and control subjects were performed using the Mann-Whitney U test.  
 
Surface based comparisons were performed using a general linear model (GLM) to test 
Bmax signal differences between control and MS patients on a vertex-by-vertex basis, 
adjusting for age and sex. A statistical threshold of p<0.05 was used, corrected for 
multiple comparisons using a Z Monte-Carlo Simulation, with 5000 iterations and a 
vertex-wise threshold of 0.05. A similar method was used to compare the cortical 
thickness between controls and patients across the whole cortex. 
 
Partial correlation analyses were employed to assess the relationship between [11C]FMZ 
binding sites and clinical measures (EDSS, 25FW, 9HPT, PASAT, MMSE, Stroop test 
and Rey Complex Figure) adjusting for the effect of age and sex in the patient 
population only (n=18).  
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The relationship between cortical thickness and Bmax across subjects both in the 
patient group and the control group, and between cortical [11C]FMZ binding sites and 
WM T2 lesion load were evaluated using Spearman’s rank correlation.  
 
Correlation between cortical Bmax and PASAT scores was also computed on a vertex-
by-vertex basis for all patients using a GLM (n=18). 
 
 
3. RESULTS 
 
3.1. Characteristics of MS patients and healthy 
controls 
 
Demographic and clinical characteristics of MS patients and controls are presented in 
table 3. 
 
A total of 8 healthy controls and 18 MS patients were included in the study. The patients 
were divided in 2 groups: RRMS (n=9) and SPMS (n=9). The control and MS groups did 
not significantly differ with regard to age (p=0.85), but RRMS subjects were younger 
than SPMS subjects. The groups were not matched for sex. We thus took into account 
both age and sex in our statistical analyses.  
 
The SPMS group had a longer disease duration compared to the RRMS group (24.3 
years vs 7.0 years). They also had higher EDSS scores (6.2 vs 2.2). 
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 Healthy 
controls 
(n=8) 
MS patients  
(n=18) 
RRMS 
patients 
(n=9) 
SPMS 
patients 
(n=9) 
Age, yr 45.4 
 [35.8-55.3] 
42.6  
[25.1-56.0] 
33.4  
[25.1-45.8] 
51.8  
[45.8-56.0] 
Sex (M/F) 6/2 7/11 1/8 3/6 
Disease 
Duration, yr 
 15.7  
[1.8-35] 
7.0 
 [1.8-20.2] 
24.3  
[12.5-35.0] 
EDSS  4.2 [1.0-7.5] 2.2 [1.0-3.0] 6.2 [5.0-7.5] 
 
Table 3: Demographic and clinical characteristics of healthy controls and MS patients 
included in the study (mean, range) 
 
 
Comparisons of physical and cognitive performance between groups were performed 
using linear regression analyses adjusting for the effect of age and sex (Table 4). The 25- 
FW could only be assessed in 14 of the MS patients. 4 patients could not complete the 
task, as they were wheelchair bound. All subjects performed the rest of the clinical 
evaluation. We found no difference between patients and controls for the 25-FW (n=14 
patients), 9HPT with nondominant hand (NDH) and cognitive tests PASAT, MMSE, or 
Rey Complex figure. Significant differences between patients and controls were found 
for the 9HPT with dominant hand (DH) and Stroop Test.  
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 Controls MS Patients 
EDSS  4.2 (2.2) 
25 FW 7.4 (3.0) 10.7 (11.1) 
9HPT- DH 20.6 (2.4) 28.4 (11.2)* 
9HPT-NDH 21.7 (3.0) 35.1 (26.8) 
PASAT 42.9 (10.4) 36.3 (11.4) 
MMSE 27.6 (2.1) 27.2 (3.3) 
Stroop test 51.6 (6.9) 45.4 (6.7)* 
Rey Complex Figure   
Copy 34.4 (1.8) 32.7 (4.4) 
Recall 19.6 (7.4) 17.7 (8.3) 
 
Table 4: Clinical measures of physical and cognitive performance for healthy controls and 
MS patients. * indicates a significant difference between the 2 groups.  
 
 
3.2. [11C]FMZ binding in the grey matter  
 
Reconstructed PET images yielded high resolution whole brain parametric maps of BZD 
receptor concentration (Bmax) that clearly localized within GM areas. The quality of the 
output can be assessed on figure 25, which presents parametric maps in a healthy 
control and in a MS patient. 
 
[11C]FMZ Bmax was 2.5 fold higher in cortical regions compared to subcortical GM: in 
the healthy control group, median cortical Bmax was 111.7 pmol/ml (88.3-124.8) and 
median subcortical GM Bmax was 43.5 pmol/ml, (37.4-51.9).  
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Figure 25: Parametric maps of the BZD receptor concentration (Bmax) in a healthy control 
(A) and MS patient (B) 
 
 
Using Spearman’s rank correlation test we found no correlation between total GM 
[11C]FMZ Bmax and age either in the entire cohort of subjects (r=-0.01, p=0.96), in the 
MS group alone (r=-0.01, p=0.96) or in healthy controls alone (r=0.36, p=-0.38), 
suggesting that age did not interfere as a major confounding factor in [11C]FMZ binding 
estimation (figure 26). However the correlation between age and volumetric 
measurements was significant both in the cortical and subcortical GM and justified 
correction for the effect of age in our statistical analyses.  
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Figure 26: Spearman rank correlation between [11C]FMZ Bmax and age across subjects. No 
correlation was found between age and [11C]FMZ Bmax in either healthy controls or MS 
patients. 
 
 
3.3. GM atrophy in MS patients 
 
GM atrophy was assessed by means of GM volume estimation in the total GM, cortical 
GM and in subcortical GM structures. GM volumes were normalized for headsize prior 
to comparison between groups. The mean cortical thickness was also estimated for the 
whole cortex and for the different lobes (frontal, parietal, temporal, occipital, insula and 
cingulate). Cortical thinning was assessed using ROI analyses and surface-based 
analyses. 
 
When total grey matter and total cortical volumes normalized for headsize were 
compared between the control group and the MS group, the difference did not reach 
significance after adjustment for age and sex (figure 27 A, B). The total volume of deep 
GM structures normalized for headsize was reduced in MS patients compared to HC 
(figure 27, C), the difference being significant after adjustment for age and sex in the 
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total subcortical GM (p=0.003), the thalami (p=0.0003) and the left caudate nucleus 
(p=0.02) (figure 27, D).  
 
The mean cortical thickness for the whole cerebral cortex was 2.44 ± 0.08 mm in 
healthy controls and 2.39 ± 0.11 mm in the whole MS group, with variations depending 
on cortical location.  On ROI analyses, cortical thickness was significantly decreased in 
MS patients compared to controls in the temporal and occipital lobes bilaterally (figure 
27, E). Vertex-by-vertex GLM analyses adjusted for age and sex failed to detect 
significant cortical thinning. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 27: A-C: Box and whisker diagrams of the volume fractions of the total GM (A), 
cortex (B) and deep GM (C) in healthy controls (HC) and MS patients.  D: Volume fraction 
of subcortical GM structures in HC and MS patients. E: Cortical thickness in the total 
cortex and cortical lobes (mm) in HC and MS patients.  Statistical comparisons were 
performed using linear regression adjusting for age and sex with a significance threshold 
of p<0.05. 
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3.4. Reduced [11C]FMZ binding in the MS GM 
 
3.4.1. In cortical structures 
 
Mean [11C]FMZ Bmax was reduced in MS patients compared to controls with a 9.4% 
decrease in the total GM and a 10% decrease in cortical GM, the difference remaining 
significant when adjusted for age and sex in the cortical GM (p=0.037, fig 28 A, B).  
 
The cortical parcellation obtained with FreeSurfer allowed a regional analysis of 
[11C]FMZ Bmax changes, showing for the MS group a significant decrease in the parietal, 
cingulate, and insular cortices of both hemispheres, and in the left frontal cortex (figure 
28, C).The estimated total amount of [11C]FMZ binding sites, defined as the product of 
the Bmax by the total volume of the structure, then normalized by head size showed a 
decrease in similar proportion that reached significance in both the total GM (-10.3%, 
p=0.03) and the cortical GM (-10%, p=0.03) (figure 29 A, B).  
 
Significant negative correlations were found between cortical thickness and cortical 
Bmax across cortical regions both in HC (r=-0.86, p= 0.0006) and in MS patients (r=-
0.98, p<2.2x10-16) (figure 30, A). But no correlation between cortical thickness and 
cortical Bmax across subjects was found either in healthy controls (r=0, p=1) or in MS 
patients (r=0.12, p=0.64) (figure 30, B).  
 
 
3.4.2. In subcortical structures: 
 
Bmax showed a non-significant trend in the subcortical GM of MS subjects (-8.8%, 
p=0.32). The difference on ROI analyses only reached statistical significance in the left 
amygdala (figure 31).   
But the total estimated number of [11C]FMZ binding sites per GM structure, showed a 
significant decrease (figure 32) in the:  
- Total subcortical GM (-17%, p=0.008)  
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- Left and right thalami (-23% and -25% respectively, p=0.001) 
- Left and right hippocampi (-15%, p=0.003 and -19%, p=0.005 respectively)  
- Left and right amygdalae (-21%, p=0.001 and -18%, p=0.02 respectively). 
 
 
 
Figure 28: ROI analyses of [11C]FMZ Bmax in cortical structures. A-B: Box and whisker 
diagrams of [11C]FMZ Bmax in healthy controls (HC) and MS patients in the total GM (A) 
and cortex (B). C: [11C]FMZ Bmax in HC and MS patients in cortical lobes. Statistical 
comparison was performed using linear regression adjusting for age and sex with a 
significance threshold of p<0.05. 
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Figure 29: ROI analyses of the estimated number of [11C]FMZ binding sites. Total FMZ 
binding sites in the total GM (A), cortex (B) of healthy controls (HC) and total MS patients.   
 
 
 
Figure 30: Spearman rank correlation between [11C]-FMZ Bmax and cortical thickness 
across cortical regions (A) and across subjects (B). A: significant negative correlation 
between mean cortical thickness and [11C]-FMZ Bmax across cortical regions in healthy 
controls (square marker, dashed regression line) and MS patients (diamond markers, 
solid regression line). B: no correlation between global cortical thickness and [11C]-FMZ 
Bmax across subjects in either healthy controls or MS patients.  
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Figure 31: ROI analyses of [11C]FMZ Bmax in deep GM structures A: Box and whisker 
diagrams of [11C]FMZ Bmax in healthy controls (HC) and MS patients in the deep GM. B: 
[11C]FMZ Bmax in HC and MS patients in individual deep GM structures. Statistical 
comparison was performed using linear regression adjusting for age and sex with a 
significance threshold of p<0.05. 
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Figure 32: ROI analyses of [11C]FMZ binding sites in deep GM structures. A: Box and 
whisker diagrams of [11C]FMZ total binding sites in healthy controls (HC) and MS patients 
in the deep GM. B: [11C]FMZ binding sites in HC and MS patients in individual deep GM 
structures. Statistical comparison was performed using linear regression adjusting for age 
and sex with a significance threshold of p<0.05. 
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3.5. Subgroup analyses of [11C]FMZ binding 
 
Two groups of patients were included in our study: RRMS (n=9) and SPMS (n=9). 
Considering the small sample size of these groups, such analyses are only exploratory 
but can provide some interesting information regarding the chronology of [11C]FMZ 
binding over the course of the disease. The results of the subgroup analyses are 
presented in figure 33.  
 
Exploratory analyses of the [11C]FMZ Bmax changes in the RRMS subgroups, compared 
to controls showed a significant decrease in RRMS patients of: 
- 11.2% (p=0.008) in total GM 
- 11.3% (p=0.008) in cortical GM  
- 13.7% (p=0.046) subcortical GM 
The total estimated number of [11C]FMZ binding sites (normalized by headsize) was 
found to be decreased by: 
- 8.4 % (p=0.046) in total GM 
- 8.1 % (p=0.046) in cortical GM 
- 14% (p=0.027) in subcortical GM  
 
When the [11C]FMZ Bmax was considered in SPMS patients, there was a moderate 
decrease that did not reach significance in either the total GM (-7.5%, p=0.14),  cortical 
GM (-8.6%, p=0.14) or subcortical GM (-4%, p=0.54).  
However, the total amount of [11C]FMZ binding sites was decreased by: 
- 12.2 % (p=0.027) in total GM 
- 11.8 % (p=0.027) in cortical GM 
- 19.6 % (p=0.006) in subcortical GM  
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3.6. Cortical mapping of [11C]FMZ binding changes  
 
It was of interest to see if we could map [11C]FMZ binding changes between groups to 
determine which cortical regions were more affected by the loss of BZD receptor sites. 
This was done using the vertex-by-vertex GLM procedure available in FreeSurfer. 
Comparisons were adjusted for the effect of age and sex and corrected for multiple 
comparisons.  
 
The vertex-by-vertex GLM procedure applied to [11C]FMZ PET data at the group level 
detected five clusters of significantly decreased [11C]FMZ Bmax in MS patients 
compared to controls (figure 34, table 5), localized in: 
- Left superior parietal gyrus (cluster-wise p-value=CWP= 0.0014) 
- Right inferior parietal gyrus (CWP= 0.0002) 
- Right supramarginal gyrus (CWP=0.0028) 
- Right rostral middle frontal gyrus (CWP=0.0312) 
- Right pars triangularis (CWP=0.0218).  
Importantly, no cluster of increased [11C]FMZ Bmax was detected.  
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Figure 34: FreeSurfer surface-based analyses of [11C]FMZ Bmax. A-H: Regions where 
[11C]FMZ Bmax was decreased in subjects with MS compared to healthy controls, after 
correction for age and sex. Left hemisphere, top (A-D) and right hemisphere, bottom (E-
H). No cluster of increased [11C]FMZ Bmax was found.  
 
 
Area of 
between-
group 
difference 
Side Cluster 
size 
(mm2) 
Maxima Voxel 
MNI Coordinates 
Patients 
mean 
(SD) 
Control 
mean 
(SD) 
CWP 
   x y z    
Superior 
Parietal 
L 1711.98 -16.5 -76.7 42.3 114.3 (8.8) 126.4 
(15.3) 
0.0014 
Inferior Parietal R 2090.25 33.7 -69.5 37.8 127.7 
(18.2) 
144.4 (9.9) 0.000
2 
Supramarginal R 1735.61 58.0 -25.7 35.6 110.7 
(10.0) 
127.1 (15.9) 0.0028 
Rostral Middle 
Frontal 
R 1214.52 44.6 26.8 31.6 107.2 
(10.0) 
122.3 
(18.0) 
0.0312 
Pars 
Triangularis 
R 1293.38 44.4 33.0 7.5 106.2 
(10.9) 
115.9 
(18.0) 
0.0218 
 
Table 5: Clusters of decreased cortical [11C]FMZ Bmax in MS patients compared to HC. 
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3.7. Relationship between [11C]FMZ binding and 
white matter lesions load  
 
To determine the impact of focal WM damage on [11C]FMZ binding, we evaluated the 
correlations between PET measures and global T2 lesion load (figure 35).  
 
T2 lesion load was estimated for each subject and averaged at 19,550 mm3 in RRMS 
patients (2,627-37,965 mm3) and 40,167 mm3 in SPMS patients (5,865-66,596 mm3). 
 
There was a significant negative correlation between T2 lesion volume fraction and 
[11C]FMZ binding sites in: 
- Cortical GM (r=-0.51, p=0.03)  
- Subcortical GM (r=-0.67, p=0.003) 
- Trend only in the total GM (r=-0.46, p=0.06).  
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Figure 35: correlation between T2 lesion load and [11C]FMZ binding sites in the cortical 
GM, subcortical GM and total GM of MS patients.  
 
 
3.8. Relationship between [11C]FMZ binding and 
clinical metrics 
 
It was of interest to evaluate the clinical relevance of our PET metrics by assessing their 
relationship with physical and cognitive performance as part of an exploratory analysis. 
 
Relationship between clinical scores and cortical [11C]FMZ binding sites was assessed 
using the entire patient cohort (table 6). Significant partial correlations were found 
between cortical [11C]FMZ binding sites and performance on: 
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- PASAT (r=0.52,p=0.04) 
- MMSE (r=0.77, p=0.0004)  
- Rey complex figure task (copy r=0.60, p=0.01; recall r=0.81, p=0.0001).  
 
 Controls MS Patients Correlation with cortical 
GM [11C]FMZ binding, 
rho(p-value) 
EDSS  4.2 (2.2) 0.17 (0.53) 
25 FW 7.4 (3.0) 10.7 (11.1) 0.04 (0.90) 
9HPT- DH 20.6 (2.4) 28.4 (11.2) 0.38 (0.15) 
9HPT-NDH 21.7 (3.0) 35.1 (26.8) 0.21 (0.43) 
PASAT 42.9 (10.4) 36.3 (11.4) 0.52 (0.04) 
MMSE 27.6 (2.1) 27.2 (3.3) 0.77 (0.0004) 
Stroop test 51.6 (6.9) 45.4 (6.7) 0.39 (0.15) 
Rey Complex 
Figure 
   
Copy 34.4 (1.8) 32.7 (4.4) 0.60 (0.01) 
Recall 19.6 (7.4) 17.7 (8.3) 0.81 (0.0001) 
 
Table 6: Clinical correlations. Clinical performances of HC and MS patients and 
correlation with cortical [11C]FMZ binding (partial correlation coefficient and p-value) 
adjusting for the effect of age and sex in the patient population (n=18).  
 
 
Correlations between cortical Bmax and PASAT performances were also tested at the 
surface-based level to determine the cortical regions associated with PASAT 
performance (figure 36, table 7). Significant positive correlations were detected in: 
- Right posterior cingulate 
- Right precentral 
- Left postcentral gyri  
No cluster with negative correlation was detected.  
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Figure 36: FreeSurfer surface-based correlations between [11C]FMZ Bmax and PASAT 
performance. Visual representation of regions where [11C]FMZ Bmax correlates positively 
with PASAT scores. Left hemisphere, top (A-B) and right hemisphere, bottom (C-D).   
 
 
Area of between-
group difference 
Side Cluster size 
(mm2) 
Maxima Voxel MNI 
Coordinates 
CWP 
   x y z  
Postcentral L 3894.97 -18.1 -33.5 61.1 0.0002 
Posterior Cingulate R 1586.47 6.4 -26.8 27.6 0.009 
Precentral R 1894.19 27.3 -21.4 63.5 0.003 
 
Table 7: GLM clusters. Regions where cortical [11C]FMZ Bmax in patients with multiple 
sclerosis (n=18) correlated positively with PASAT scores on surface based analyses. No 
negative correlation was found. 
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1. IN VIVO QUANTIFICATION OF NEURONAL 
DAMAGE IN MS 
 
This work aimed to quantify the neuronal contribution to GM damage in MS using high 
resolution PET and the neuronal marker [11C]FMZ. It is, to our knowledge, the first 
controlled in vivo study demonstrating changes in GABAA receptor density in MS 
patients. We found, using both a ROI and a surface-based approach, that cortical 
[11C]FMZ binding was reduced in MS subjects, and that surface-based analyses allowed 
mapping of cortical damage at the group level. In the subcortical GM, a significant 
decrease in GABAA receptor sites but not density was detected in the thalami, 
hippocampi and amygdalae. Subgroup analyses suggested that [11C]FMZ binding 
reduction was already present in RRMS subjects, whereas GM atrophy was barely 
detected at this stage. Finally, cortical GABAA receptor content was found to correlate 
positively with cognitive performance, suggesting the clinical relevance of this 
quantitative measure.  
 
MS is a diffuse chronic demyelinating disease of the CNS affecting not exclusively 
neurons, but also macroglial, microglial and inflammatory cells. In order to detect 
neuronal damage that could occur randomly in the GM of MS subjects, we took 
advantage of recent methodological optimizations. First, all PET images were acquired 
on a high-resolution research tomograph (HRRT, Annex B) which has one of the highest 
sensitivity and spatial resolution among currently available PET scanners (2.5 mm) and 
allows accurate localization of alterations in GABAA receptor density within the cortical 
ribbon.  Secondly, we used the partial saturation method [216] to estimate receptor 
concentration from a single FMZ injection and without arterial blood sampling. This 
previously validated method exploits the natural decrease of bound ligand concentration 
over the duration of the experiment after labeled/unlabeled FMZ co-injection and 
provides an absolute quantification of BZD receptors concentration (Bmax). Thirdly, we 
supplemented ROI-based analyses with a surface-based approach to regionally map the 
differences in cortical [11C]FMZ binding between MS patients and controls. While ROI 
analyses are constrained to predetermined GM regions either manually or automatically 
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delineated, surface-based analyses allow a vertex-by-vertex comparison of [11C]FMZ 
Bmax differences between subjects. This technique has been shown to improve the 
reliability and detectability of PET signal changes [228] as a result of processing steps 
that minimize partial volume effect (PVE) from the white matter and CSF such as 
surface-based smoothing and sampling of PET measures halfway between the white and 
pial surfaces.  
 
[11C]FMZ Bmax, which estimates the density of GABAA receptors, showed more 
significant changes in the mildly atrophic RRMS subgroup compared to the most 
atrophic SPMS subjects. This was all the more unexpected as the influence of any partial 
volume effect should have resulted in more significant signal decrease in the grey matter 
of patients with marked atrophy. Therefore the impact of PVE on our results is probably 
minor, and this apparent discrepancy suggests that atrophy could induce an artificial 
increase in GABAA receptor density estimated by [11C]FMZ Bmax. Such an artificial 
increase in density becomes easy to understand if we consider that the underlying 
substrate for grey matter atrophy is independent from the synaptic component [107]. 
Therefore atrophy partly masks the decrease in GABAA receptors number, as far as it is 
measured by their density in a reduced volume. Interestingly, quantifying the total 
number of GABAA receptors sites per region re-established the expected result by 
showing greater loss in the SPMS subgroup, which corroborated this hypothesis. Overall 
these two metrics, Bmax, and total amount of GABAA receptors, may each be useful in a 
clinical setting: the Bmax analysis provides a sensitive tool to detect and regionally map 
the neuronal component of grey matter pathology, especially in cortical regions, as soon 
as the earliest stages of the disease, when atrophy is only minor; the total amount of 
GABAA receptors estimates the overall neuronal and synaptic pathology in regions of 
interest, and may provide measures suitable for longitudinal follow up that will not be 
biased by progressive atrophy. Further work investigating how we can minimize the 
influence of any PVE on this second metric may be needed.  
 
The pathological correlates of [11C]FMZ binding changes detected in MS remain to be 
elucidated and may not be univocal. GABAA receptors are widely expressed by CNS 
neurons, both inhibitory and excitatory, and are enriched at axo-synaptic contacts 
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[229]. Therefore quantification of [11C]FMZ binding, while assessing mainly inhibitory 
neurotransmission, is not an intrinsic measure of GABAergic neurons themselves. 
Moreover, variations of GABAA receptor content is not expected to exclusively reflect 
neuronal death or loss, and may also indicate dendritic or synaptic changes. In the 
rodent EAE model, impaired GABA transmission has been reported in the striatum and 
hippocampus [230] [231], along with drastic dendritic and synaptic alterations from the 
earliest inflammatory phase of the disease [155]. Reduction in flunitrazepam-sensitive 
GABAA receptor density without changes in affinity was also found in cortical 
synaptosomes of EAE rats [232]. In post-mortem samples from MS subjects, significant 
synaptic loss along with less pronounced evidence of neuronal death were described in 
the neocortex [83] [105], as well as in deep GM structures, notably the thalamus and 
hippocampus [110] [109]. Post mortem studies have confirmed a reduction in GABAA-
related gene transcripts and loss of inhibitory interneurons in MS, supporting the notion 
that cortical neurons of chronic MS patients have significantly decreased inhibitory 
innervation [123]. Cawley et al [233] provided evidence of reduced GABAA levels in the 
hippocampus and sensorimotor cortex of SPMS patients using MR spectroscopy and 
suggested that lower GABAA concentrations correlated with reduced motor function. 
Injury of GABAergic inhibitory systems is an early event thought to trigger excitotoxicity 
via up-regulation of glutamate-mediated neurotransmission resulting in extensive 
neuronal and synaptic damage [234] [235].  Impaired GABAergic transmission might 
also lead to neurodegeneration by increasing the energy expenditure of neurons that 
have a reduced capacity to produce ATP due to mitochondrial dysfunction [123]. 
Depending on the disease stage, [11C]FMZ binding changes described in MS subjects 
could therefore reflect a combination of synapse/dendrite damage and neuronal loss.  
 
Generalized GM atrophy in MS has been widely reported by histopathological [105] 
[112] and MRI studies [115] [147] [236] [237] [238] [239]. In this small cohort, grey 
matter atrophy was easily identified in the deep grey matter of patients, and was 
detectable but not significant at the relapsing stage, especially in cortical regions. Recent 
studies have shed light on the relationship between MRI-measured cortical atrophy and 
neuronal damage in MS [107] [154]. The authors have shown that neurodegenerative 
processes drive GM atrophy in the cortex, as they found significant correlations between 
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cortical volume and neuronal density or neuronal numbers, but no correlations with 
myelin density. In the present study, cortical thinning was significant in the temporal 
and occipital lobes bilaterally, reaching about 4-5% in ROI analyses.  We related cortical 
thickness to [11C]-FMZ binding, as a potential marker for neuronal integrity in vivo. 
Correlations were assessed both across cortical regions and across subjects. First, we 
found a linear decrease in mean [11C]-FMZ Bmax with increasing global thickness across 
cortical lobar areas, both in healthy controls and MS patients separately. Lafougere et al. 
[240] described a similar relationship in heterotypical and temporo-occipital 
homotypical cortices. However, when we assessed the relationship between cortical 
thickness and [11C]-FMZ binding across subjects in the MS group and the healthy 
control group, no correlation was found. These results do not antagonize the recent 
findings cited above. It can be postulated that [11C]FMZ PET metrics reflect not only 
neuronal loss, but also subtle neurodegenerative changes such as synaptic loss or 
dendritic transections which may precede neuronal loss and are not fully captured by 
measures of GM volume. Therefore measuring neuronal damage by PET and GM 
volume by MRI does not provide redundant information and the combined use of 
[11C]FMZ PET and MRI could synergistically contribute to a better evaluation and 
understanding of neurodegeneration in MS.  
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2. CLINICAL RELEVANCE OF PET WITH [11C]FMZ 
 
Despite uncertainties regarding the interpretation of [11C]FMZ PET data at the sub-
cellular level, the clinical relevance of this imaging biomarker was suggested by our 
exploratory analyses as it was found to correlate with several clinical measures. The lack 
of significant cross-sectional correlation between [11C]FMZ binding and the main 
metrics of physical disability (EDSS, 25-foot walk test) in this small population was not 
surprising as these metrics are drastically influenced by spinal cord pathology, a 
condition that could not be taken into account in a study focusing on the brain. 
However, we found significant correlations between cortical [11C]FMZ binding and 
performance on several cognitive tests. Correlations were found with MMSE, a general 
cognitive scale, PASAT, a widely used test evaluating attention, working memory and 
information processing speed, and Rey Complex Figure Test which captures visuo-
spatial processing. All these cognitive domains are amongst the most affected in MS 
[241]. This reinforces the view that cortical neuronal damage may be a key pathological 
substrate leading to cognitive deficits in MS, a hypothesis previously suggested by 
structural MRI studies [242] [243] [244], or MR spectroscopy [245] [246]. Surface-
based analyses enabled us to map several relevant cortical areas for PASAT 
performance, which were located in the right posterior cingulate cortex (PCC), the left 
postcentral gyrus and the right precentral gyrus, with a trend in the left PCC (significant 
correlation before correction for multiple comparisons, data not shown). These areas are 
consistent with current knowledge as postcentral and precentral gyri have been 
described as belonging to the PASAT network [247] [248] and PCC has been identified 
as a key structure involved in adaptative cerebral plasticity in MS [247]. PCC is a highly 
connected structure acting within the default mode network (DMN), and controlling the 
focus of attention through its interaction with the prefrontal cortex [249]. PCC 
dysfunction together with DMN disconnection may be possible triggering events for the 
onset of cognitive symptoms in MS [243] [250] [251]. 
 
  
 103 
3. UNDERLYING MECHANISMS OF NEURONAL 
DAMAGE IN MS 
 
3.1. Relationship between WM and GM damage 
 
The mechanisms underlying structural and functional neuronal damage within the MS 
grey matter haven’t yet been elucidated, especially its relation to demyelination and 
inflammation. Of particular interest is the association between neurodegeneration and 
focal white matter damage, the most striking feature of the disease. Our group of 
patients presented a wide range of T2 lesion burden. Our results showed a significant 
yet moderate relationship between WM T2-weighted lesion load and the cortical GABAA 
receptors. The relationship was stronger in the subcortical GM.  Our results support the 
notion that focal damage to WM tracts contribute at least partly to the on-going damage 
to neuronal and synaptic structures in the MS GM. This might be explained by 
underlying mechanisms of anterograde or retrograde degeneration [85]. Consistent with 
this notion that WM and GM are inter-related processes, several MRI studies have 
reported significant correlation between WM damage and GM atrophy, in deep GM 
structures [252] or cortical structures [253]. Longitudinal studies analyzing GM atrophy 
using VBM or similar techniques [254] [255] showed an association between global WM 
lesion volumes and increasing GM volume loss especially in fronto-temporal areas. 
Bernfeldt et al. demonstrated more widespread cortical GM atrophy in patients with 
longitudinal changes in T2 lesion volumes compared to patients with stable lesion loads 
[255] [256].  Location of WM damage was shown to contribute to clinical disability 
[238]. Similarly, the spatial distribution of WM T2 lesions is relevant to GM volume 
loss. Mulhau et al recently unveiled a significant spatial relationship between WM 
lesions and thalamus pathology [257]. This might be further explained by the fact that 
the thalamus is a relay organ, receiving input from multiple connected WM fibers. In the 
MS cortex, highly connected structures such as the cingulate gyrus or the insula appear 
more prone to volume loss, reinforcing the role of WM disconnection in the 
development of GM atrophy. WM lesions, however only seem to account for less than 
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half of the variance in GM atrophy in the early stages of the disease [258] and 
histopathological studies of late MS patients have outlined a dissocation between plaque 
load and pathological markers of neurodegeneration [259] [112]. These findings suggest 
the impact of other processes in the progression of GM and specifically neuronal 
damage.  
 
More subtle and diffuse changes occurring within the NAWM may also contribute to the 
cortical abnormalities observed using [11C]FMZ PET. Such relationship was not 
evaluated in our pilot study. Quantitative MRI metrics have been shown to be sensitive 
to microstructural changes in post-mortem tissue [260] [112] and have been used to 
quantify white matter integrity in MS. In a recent paper, Kolasinski et al. also suggested 
that functional anatomical connectivity might be relevant to the spread of MS pathology 
in a “tract-specific pattern” [112]. Focal changes in MRI cortical thickness showed a 
clear intra-tract correlation with changes in WM microstructure. The correlation was 
reproduced using traditional histological metrics or DTI-derived measures of WM 
integrity. Tract-specific measures of WM integrity were not only found to better 
correlate with corresponding cortical thickness but also related better to measures of 
disability [179] than measures of global WM changes. Longitudinal study design could 
help understand the temporality of these events and determine whether tract-specific 
WM damage predicts GM as suggested by prior MRI work [253] 
 
In a new prospective project (clinicaltrial.gov ID: NCT01651520), we are planning to 
assess the chronology of occurrence and the prognostic value of neuronal damage 
measured by [11C]FMZ PET in early RRMS and PPMS patients. Acquisition of 
multimodal MRI data at each timepoint will also help address the relationship between 
GM and WM pathology. Four groups of subjects will be included: i) patients with RRMS 
with less than 5 years disease duration (revised Mc Donald criteria, n=20); ii) patients 
with RRMS with over 5 years but less than 10 years disease duration (n=20); iii) 
patients with a primary progressive MS (PPMS) with less than 10 years disease duration 
(n=20); iv) healthy volunteers matched for age and sex (2/3 matched with RRMS 
patients; 1/3 matched with PPMS patients). Preliminary data of a subgroup of early 
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RRMS patients (n=9, age= 35.1 years, mean disease duration=23 months) and controls 
(n=7, age=32.3 years) is available. In a preliminary work (unpublished data), we related 
T2 lesion load and NAWM FA within 3 WM tracts (thalamo-prefrontal, cingulate and 
cortico-spinal) to [11C]FMZ Bmax in anatomically related cortical areas (rostral middle 
frontal, posterior cingulate, precentral) in patients only. The cross-sectional correlations 
between these metrics failed to show significant relationship between focal or diffuse 
intra-tract WM damage and GM neuronal injury (figure 37). A trend was found between 
FA within cingulate white matter tracts and posterior cingulate Bmax (rho=-0.40, 
p=0.097). Considering the short disease duration, follow-up of these subjects will be 
very informative to determine the nature and chronology of a relationship between 
these two phenomena.  
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Figure 37: Correlations between T2 lesion load and NAWM FA within 3 white matter tracts 
(thalamo-prefrontal, cingulate and cortico-spinal) and [11C]FMZ Bmax in anatomically 
related cortical areas (rostral middle frontal, posterior cingulate, precentral) in early 
RRMS patients (unpublished data). 
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3.2. Relationship between GM demyelination and 
neurodegeneration 
 
The in vivo relationship between cortical neuronal damage and cortical demyelination 
also needs to be investigated. Studies of autopsy material have determined that 
demyelination is extensive in the GM of patients with MS, especially in the secondary 
progressive phase of the disease [84].  The seminal work by Peterson et al. [83] 
identified axonal transections, dendritic transections and neuronal deaths by apoptosis 
within areas of cortical demyelination in MS brains. Wegner et al. [105] later suggested 
that neuronal degenerative changes and synaptic loss occur within neocortical lesions, 
whereas non-lesional neocortex does not show significant changes in neuronal or 
synaptic density. Furthermore, reduction in synaptic density and decreased expression 
of neuronal proteins involved in neuronal survival were also reported in demyelinated 
hippocampi from post-mortem MS brains [109]. However, other studies have been 
challenging these findings and described extensive neuronal and dendritic loss as well as 
evidence of mitochondrial dysfunction in myelinated cortical areas [261] [124]. The 
methodological and sampling differences between these studies limit their 
comparability. Thus more work is needed, as it remains important to determine to what 
extent GM demyelination and neurodegeneration are inter-related. This relationship 
might be explored in vivo in a multimodal approach by combining [11C]-FMZ high 
resolution PET with MR imaging sequences able to visualize GM lesions such as Double 
Inversion Recovery (DIR).  
 
In a presentation by Theodore Soulier, MSc, highlighted at the ECTRIMS meeting in 
Copenhagen in October 2013, we addressed this specific question [262]. In our new 
cohort of 9 early RRMS patients, 8 presented DIR-visible cortical lesions and were 
selected for preliminary analyses (figure 38). We compared [11C]FMZ Bmax within DIR 
lesions and cortical normal-appearing GM (NAGM). A significant 16.4% decrease in 
Bmax (p=0.023) was found in cortical lesions (86,35 pmol/mL ± 4,64 pmol/mL) 
compared to NAGM (103,31 pmol/mL ± 2,93 pmol/mL) (figure 39). No significant 
difference was found between NAGM Bmax in MS patients compared to healthy 
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controls. These findings suggest that a significant level of neuronal injury might occur in 
conjunction with demyelination at the early stages of the disease, and be limited to areas 
of GM demyelination. Neuronal injury in demyelinated GM may relate to acute damage 
to axo-dendritic processes secondary to inflammation [81]. Indeed, Lucchinetti et al. 
reported significant inflammation within early cortical lesions, which differed from 
chronic GM lesions in that respect. The authors also described neuronal damage 
occurring on a background of inflammation at this stage supporting the notion of a 
secondary neurodegenerative process, in the context of local inflammation in early MS 
[86]. The inflammatory milieu may alter expression and phosphorylation of AMPA 
receptors or downregulate genes involved in glutamatergic neurotransmission, thus 
promoting neuronal and synaptic damage via glutamate accumulation and excitotoxicity 
[263]. As the disease evolves, inflammation becomes much less pronounced within 
cortical lesions and the relationship between GM demyelination and neuronal/synaptic 
injury may not be as exclusive. Longitudinal follow-up of our subjects as well as 
assessment of patients at different stages of the disease may provide greater insights on 
the evolving interplay between these two processes.  
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Figure 38: Processing steps undertaken to analyze and compare Bmax within DIR-visible 
cortical lesions (CLs) and normal appearing cortical GM (NAGM). 
 
 
                        
Figure 39: Comparison of mean [11C]FMZ Bmax in cortical NAGM (cNAGM) and within 
DIR-visible cortical lesions (-16.4%, p=0.023).  
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3.3. Other aspects 
 
Other mechanisms at play in the MS grey matter have been proposed. Evidence of 
cerebral hypoperfusion in MS is currently gaining some attention as it may negatively 
impact an already precarious energy balance in neuronal cells [130]. From a clinical 
standpoint, reduction in cerebral blood flow (CBF) has been associated with cognitive 
deficits and fatigue in MS patients [264] [134].  
 
In a recent work led with the team of Dr Wolinsky at the University of Texas at Houston 
and recently presented at ECTRIMS, I was able to show that hypoperfusion is a 
widespread phenomenon in the MS GM, which can be assessed using non-invasive MRI 
techniques. We performed pseudo-continuous arterial spin labeling (pCASL) MRI in 34 
MS patients (5 CIS, 24 RRMS, 5 SPMS) and 19 healthy controls and used a region-of-
interest and a surface-based approach to evaluate cortical and subcortical GM blood 
flow differences between groups. ROI analyses showed diffuse decrease of CBF in MS 
neocortex and DGM structures compared to controls, in proportions that surpassed that 
of atrophy measures (figure 40). Thalami and Pallidi showed the most significant 
decrease in CBF among DGM structures (-29% and -25% respectively, p<0.005 
adjusting for age and sex). Fronto-temporal cortices were among the most affected in 
surface-based analyses (figure 41, table 8). We also found a moderate yet significant 
positive relationship between cortical hypoperfusion and cortical volume at the cross-
sectional level (rho=0.36, p=0.03). 
 
Manipulation of 2D pCASL data can be challenging and care must be taken to apply 
partial volume effect correction algorithms to limit cross-tissue contamination. Surface-
based analyses present a definite advantage in this regard as we have discussed earlier.  
The interpretation of our results also requires caution. We will need to establish that 
cerebral hyperperfusion in MS does not simply reflect contemporaneous loss of neurons 
and atrophy but is rather an early and integral feature of MS pathophysiology. 
Debernard et al. [131] provided evidence of cerebral hypoperfusion at the very early 
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stages of MS before atrophy was even detectable. In our cohort, the decrease in CBF was 
of greater amplitude than corresponding atrophy measures. Other objective findings 
support the notion of primary hypoperfusion in MS. Elevated levels of Endothelin-1 
(ET-1), a vasoconstrictive agent, have been found in serum and CSF of MS patients 
[265] [266] and were associated with reduced blood flow velocities [267]. ET-1 was also 
detected in reactive astrocytes in post-mortem MS brains [268]. Ultimately, 
interrogation of longitudinal data will be of great importance, as it will allow us to 
determine whether hypoperfusion heralds or follows irreversible tissue loss. 
Combination of perfusion MRI techniques, such as pCASL, with [11C]FMZ PET could 
help more specifically define the role of cerebral hypoperfusion in neuronal pathology. 
pCASL data was acquired in a group of early RRMS patients and healthy controls that 
will be used to evaluate the relationship between GM blood flow and [11C]FMZ bmax 
both cross-sectionally and longitudinally. This could potentially unveil novel pathways 
of tissue destruction in MS and contribute to the development of therapies targeting the 
neuronal compartment. 
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Figure 40: ROI analyses of cerebral blood flow (CBF, mL/100g/min) in deep GM structures 
(top) and cortical lobes (bottom). In DGM structures, maximum decrease of CBF was 
found in the Thalami (-29%, p=0.00005 and -28%, p=0.0002) and Pallidi (-25%, p=0.003 
and -24%, p=0.003). Global cortical CBF was 44.0 mL/100g/min (±10.6) in MS patients vs 
50.4 mL/100g/min (±9.8) in controls (-13%, p=0.01). Most cortical structures were hypo-
perfused in MS patients. 
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Figure 41: Surface-based comparisons CBF between MS patients and healthy controls. The 
vertex-by-vertex GLM procedure applied to CBF data at the group level (after adjustment 
for the effect of age and sex and correction for multiple comparisons) detected eight 
clusters of significantly decreased blood flow in MS patients compared to controls. No 
cluster of increased CBF was detected.  
 
 
Table 8: Clusters of decreased CBF in MS patients compared to controls detected by 
surface based analyses.  
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4. FUTURE ROLE OF [11C]FMZ PET IN MS  
 
With this pilot work, we have shown that PET with [11C]FMZ could be performed and 
adequately quantified in a non-invasive manner in MS patients to detect early neuronal 
injury to the GM. PET has also been used to investigate underlying pathophysiology of 
neuroinflammation, demyelination and remyelination in MS. In the particular case of 
[11C]-labeled tracers, the need and high cost of on-site cyclotron production of isotopes 
has limited the availability and widespread application of PET. Fluorinated analogs 
[269] have been proposed and should enable the integration of FMZ PET in clinical 
practice or for evaluation of novel therapies targeting the neuronal compartment.  
 
Meanwhile, [11C]FMZ PET has the potential to inform our understanding of non-
conventional MRI techniques in the assessment of neuronal pathology. As a specific 
marker of the neuronal compartment, [11C]FMZ may be used to evaluate the validity and 
specificity of neuroimaging techniques in vivo. It may also be used to test mechanistic 
hypotheses by combining imaging approaches, in which the strengths of MRI may add 
to those of PET. 
 
In our pilot cohort of MS patients, we had set out to compare [11C]FMZ binding, glucose 
metabolism evaluated using PET with [18F]FDG and multimodal MRI metrics in the 
thalamus of MS patients and controls (figure 42). In agreement with prior findings, we 
found higher FA values in MS patients compared to healthy controls. This increase, even 
though not significant, was more pronounced in progressive patients. MTR 
modifications were minor in the thalamus. This is not a surprising finding since MTR 
has been shown to be mainly affected by myelin content rather than neuronal damage. 
Spectra analysis showed a slight decrease in NAA/Cr ratio in progressive patients, due 
in equal proportions to a decrease in NAA (neuronal injury) and increase in Creatine 
(gliosis). There was a moderate decrease in neuronal metabolism in RR patients that 
could reflect early disruption between thalamus nuclei and the cortex as suggested by 
Derrache et al. (2006). However this difference did not reach statistical significance. No 
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change in metabolism was observed in progressive patients. This might be explained by 
the significant volume reduction observed in this structure, which could induce an 
artificial increase in FDG uptake. Please note that no arterial blood sampling for PET 
quantification was performed. Overall, changes measured with [11C]FMZ were of much 
greater amplitude than those noted with multimodal MRI or PET using FDG, suggesting 
that [11C]FMZ PET may provide a more sensitive quantitative marker of thalamic injury. 
This approach and correlations between the different metrics need to be validated in a 
larger group of MS patients.  
 
      
Figure 42: Patients vs controls comparisons of [11C]FMZ, [18F]FDG and multimodal MRI 
metrics in the thalamus. Unpublished data from our pilot cohort.  
 
A novel multishell DTI imaging and modeling technique has been introduced to 
measure neurite density and orientation dispersion (NODDI) in vivo [270]. This 
technique provides neurite orientation dispersion indices (ODI) thought to quantify the 
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pattern of sprawling dendritic processes. Grussu et al. at a recent ECTRIMS meeting 
presented a meaningful comparison of NODDI and histopathological measures in the 
lumbar spine of MS patients and demonstrated that ODI correlated with the circular 
variance or spread of neuritis [271]. ODI in the DGM of RRMS patients has been shown 
to correlate with physical disability scores [272]. In a future study, we plan investigate 
the relationship between FMZ binding and dendritic arborization changes assessed with 
NODDI at 7T from the early phases of RRMS and PPMS. This will contribute to further 
our understanding of the early neurodegenerative processes occurring in the MS GM.  
 
Furthermore, functional neuroimaging (fMRI) studies have highlighted the role of brain 
plasticity and cortical reorganization in disability progression in MS, suggesting that 
increased cortical recruitment might attenuate the consequences of MS-related tissue 
damage on physical and cognitive performance. Several groups have shown that MS 
patients with normal cognitive performance exhibit greater brain activation compared 
to controls during a cognitive task [248] [273] [247]. Moreover, subjects with MS recruit 
additional brain areas, usually not involved in the execution of the task. With the 
progression of the disease and the appearance of clinical symptoms, this compensatory 
mechanism tends to fail, and decreased activation is usually observed in late-stage MS 
in task-related fMRI studies [274]. A more recent approach, resting state fMRI, allows 
investigation of functional connectivity and cortical reorganization without the 
challenges of task-active fMRI investigation [275]. Louapre et al. showed that functional 
connectivity in the default-mode network and the fronto-parietal attention networks 
was selectively impaired in MS patients with severe early cognitive deficits [243]. In a 
recent paper, Roosendaal et al. demonstrated that early functional changes at rest could 
be detected in CIS patients, and that these changes were lost at later stages of the 
disease [276]. The authors suggested that cortical reorganization of brain networks is an 
early and finite phenomenon in MS, which may be hindered by increasing structural 
injury. A question thus remains: what drives the extinction of brain plasticity 
mechanisms as the disease progresses? To answer this question, the dynamic relation 
between underlying structural abnormalities such as GM neuronal pathology and 
functional connectivity needs to be investigated further, and may be addressed by 
combining resting-state fMRI and [11C]FMZ PET.  
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5. LIMITS OF PRESENT STUDY 
 
The work presented here has some limitations. The sample of MS patients and controls 
is small and rather heterogeneous. The sex ratio between patients and controls was not 
matched. Similarly, while the control and MS groups did not differ with regard to age, 
the RRMS subjects were significantly younger than their SPMS counterparts. 
Consequently, the results of this pilot study will need to be replicated in a larger and 
homogeneous cohort of MS patients, with adequate matching to a control population. 
The study of early MS patients (<5 years) is attractive as GM atrophy at this stage is not 
prominent and may not confound measurements of the density of BZD receptors using 
[11C]FMZ PET. This will also help us elucidate the early phenomena at play in the MS 
GM. 
 
The cross-sectional design of this work can help us appreciate the correlations between 
neuronal damage and clinical metrics at one point in time. In order to fully understand 
the temporal relationship between early neuronal damage and disability in MS, 
longitudinal follow up of MS patients will be necessary. This is also true to understand 
the interplay between neuronal damage and other aspect of MS pathophysiology such as 
WM focal lesions, WM diffuse pathology or GM demyelination. With these objectives in 
mind, we have continued to enroll in new longitudinal studies of early RRMS and PPMS 
patients aiming to assess the prognostic value of [11C]-FMZ PET and the relationship 
between neuronal damage and other important processes as the disease evolves.  
 
Finally, some technical limitations need to be brought to attention. While we have taken 
steps to limit the influence of partial volume effect in the study of cortical [11C]-FMZ 
binding, by means of surface-based smoothing and sampling of PET measures halfway 
between the white and the pial surface in our surface based analyses, new processing 
techniques should allow us to further limit its unavoidable impact on PET data. Steps 
will be taken to investigate this issue. 
 
 
 118 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Conclusion 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 119 
Overall this work highlights the potential of [11C]FMZ PET as a new biomarker of 
neuronal pathology in MS, which might lead to greater insights into the 
neurodegenerative mechanisms involved in MS. Further longitudinal studies will 
determine the chronology of [11C]FMZ binding in MS, the prognostic value of this 
technique and the interplay between neuronal damage and other aspects of MS 
pathophysiology.  
 
[11C]FMZ PET-derived metrics may also be of great interest for trials evaluating 
neuroprotective drugs. The high cost of PET examination together with the restricted 
availability of [11C]FMZ could impede a large application of this technology in a very 
near future. The production of a fluorinated analog of this tracer should facilitate such 
clinical applications, and allow innovative pathophysiological studies.  
 
Combining [11C]FMZ PET with advanced MRI sequences will help clarify the relative 
contribution of white matter or cortical demyelination to neuronal damage and help 
evaluate the impact of neuronal damage on structural and functional brain connectivity. 
FMZ PET studies may improve our understanding of the neuronal substrate of cognitive 
deficits in MS. By investigating predominantly inhibitory neurotransmission through 
GABAA receptors, [11C]FMZ PET could provide insights on functional mechanisms 
underlying MS-related cognitive dysfunction: cortical neuronal synchrony, which is 
regulated by GABAergic neurotransmission, is considered mandatory for cognitive 
processing [277], and could emerge as a key substrate for the pathophysiology of MS 
cognitive deficits, as previously suggested in schizophrenia or Alzheimer’s disease [278] 
[279].  
 
 
 
 
 
 
 
       
 120 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Annex 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 121 
1. ANNEX A: EDSS (from nationalmssociety.org) 
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2. ANNEX B: PET scanners 
 
 
 
Different types of available PET scanners with corresponding spatial resolution.  
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3. ANNEX C: DESIKAN-KILLIANI ATLAS 
 
 
 
The Desikan-Killiani atlas is an automated labeling system that was developed for 
subdividing the human cerebral cortex on MRI into gyral based regions of interest 
(ROIs). It was created using a dataset of 40 MRI scans with 34 manually identified 
cortical ROIs in each in each individual hemispheres. 
Source: An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral 
based regions of interest. Rahul S. Desikan,
 
Florent Segonne,
 
Bruce Fischl,
 
Brian T. Quinn, Bradford C. 
Dickerson,
 
Deborah Blacker,
 
Randy L. Buckner,
 
Anders M. Dale,
 
R. Paul Maguire,
 
Bradley T. Hyman,
  
Marilyn S. Albert,
  
and Ronald J. Killiany. NeuroImage 31 (2006) 968 – 980 [280].  
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Titre de la thèse en Français : 
Imagerie de la dégénérescence neuronale dans une maladie démyélinisante: la sclérose 
en plaques.  
 
Résumé : 
La sclérose en plaques (SEP) a longtemps été considérée comme une affection 
inflammatoire démyélinisante de la substance blanche. (SB) Hors, de nombreuses 
études ont démontré l’implication extensive de la substance grise (SG).  La souffrance 
neuronale joue un rôle majeur dans la détérioration physique et cognitive des patients 
atteints de SEP. Le développement de nouvelles techniques d’imagerie capables de 
quantifier cette atteinte neuronale est devenu crucial. 
Grace à la tomographie par émission de positons (TEP) et au radiotraceur 
[11C]flumazenil ([11C]FMZ), antagoniste du récepteur central aux benzodiazépines, nous 
avons quantifié de façon non-invasive la souffrance neuronale de la SG chez des patients 
atteints de SEP à différents stades de la maladie.  
Une cohorte de 18 patients atteints de SEP a été comparée à 8 sujets sains. Les 
participants ont bénéficié d’une évaluation clinique, cognitive, et radiologique par TEP 
au [11C]FMZ et IRM. Les données TEP ont été évaluées par région d’intérêt et vertex-à-
vertex.  
Des réductions significatives de l’activité TEP au [11C]FMZ ont été mises en évidence au 
sein de la SG corticale et sous-corticale des patients comparés aux contrôles. Ces 
changements étaient présents dès le stade rémittent de la maladie et corrélaient 
modérément avec la charge lésionnelle de la SB. L’activité TEP corticale était aussi 
associée à la performance cognitive des patients. 
Cette étude pilote est la première à quantifier in vivo la souffrance neuronale chez des 
patients atteints de SEP. Nos résultats permettent de proposer la TEP au [11C]FMZ 
comme marqueur spécifique et discriminant de l’atteinte neuronale de la SG dans la 
SEP. 
 
Mots clés : sclérose en plaques, neurodégénérescence, TEP, IRM, Flumazenil, 
récepteurs GABAA. 
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Titre de la thèse en anglais: 
Imaging the neurodegenerative component of a demyelinating disorder : multiple 
sclerosis. 
 
Résumé en anglais : 
Multiple sclerosis (MS) has long been regarded as an inflammatory demyelinating 
disorder of the white matter. But post-mortem studies have recently shed light on the 
extensive involvement of the grey matter (GM). Neuronal damage, characterized by 
synaptic and dendritic loss as well as neuronal apoptosis, is thought to be a major 
substrate of physical and cognitive deterioration in MS patients. There is a crucial need 
for new imaging techniques able to specifically assess neuronal damage in MS.  
Using positron emission tomography (PET) with [11C]flumazenil ([11C]FMZ), an 
antagonist of the central benzodiazepine site located within the GABAA receptor, and a 
non-invasive quantification method, we measured and mapped neurodegenerative 
changes in the GM of patients with MS at distinct disease stages. 
A cohort of 18 MS patients was compared to 8 healthy controls and underwent 
neurological and cognitive evaluations, high-resolution dynamic [11C]FMZ PET imaging 
and brain MRI. PET data were evaluated using a region of interest and a surface-based 
approach. 
[11C]FMZ binding was significantly decreased in the cortical and subcortical GM of MS 
patients compared to controls. These changes were significant in both progressive and 
relapsing-remitting forms of the disease and correlated moderately with white matter 
lesion load. [11C]FMZ cortical binding was also associated with cognitive performance. 
This pilot study is the first to quantify in vivo the neurodegenerative changes occurring 
in MS. Our results show that PET with [11C]FMZ could be a promising and sensitive 
quantitative marker to assess and map the neuronal substrate of GM pathology in MS. 
 
Key words: multiple sclerosis, neurodegeneration, PET, MRI, Flumazenil, GABAA 
receptors. 
    
 
